dacarbazine has been researched along with Skin Neoplasms in 606 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 141 (23.27) | 18.7374 |
| 1990's | 94 (15.51) | 18.2507 |
| 2000's | 190 (31.35) | 29.6817 |
| 2010's | 163 (26.90) | 24.3611 |
| 2020's | 18 (2.97) | 2.80 |
| Authors | Studies |
|---|---|
| Cecchini, AL; Cecchini, R; da Silva Brito, WA; Lopes, NMD; Luiz, RC; Marinello, PC; Sanches, LJ | 1 |
| Agorio, CI; Chabalgoity, JA; Chilibroste, S; Mónaco, A; Moreno, M; Plata, MC; Vola, M | 1 |
| Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y | 1 |
| Hagelstein, V; Klee, G; Kurzhals, JK; Langan, EA; Terheyden, P; Zillikens, D | 1 |
| Deng, Y; Li, J; Lu, Q; Pei, J; Su, Z; Yang, Y; Zeng, X; Zhang, Y; Zhong, Y | 1 |
| Amini, M; Baradaran, B; Firouzamandi, M; Mohammadi, A; Najafi, S | 1 |
| Amaral, JD; Francisco, AP; Gaspar, MM; Godinho-Santos, A; Matias, M; Mendes, E; Perry, MJ; Pinho, JO; Rodrigues, CMP | 1 |
| Beberok, A; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Ascierto, PA; Becker, JC; Cascinu, S; Catania, C; Danielli, R; Dummer, R; Eigentler, T; Elia, G; Garbe, C; Hauschild, A; Neri, D; Romanini, A; Trefzer, U; Weide, B | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Ascierto, PA; Blank, CU; Chapman, PB; D'Amelio, A; Demidov, LV; Dutriaux, C; Gasal, E; Grob, JJ; Gutzmer, R; Haas, T; Hauschild, A; Kefford, R; Kiecker, F; Lebbé, C; Millward, M; Mookerjee, B; Ribas, A; Rutkowski, P; Schadendorf, D | 1 |
| Bentley, MVLB; Borgheti-Cardoso, LN; Caron, AL; Kravicz, M; Praça, FG; Silvestrini, AVP; Viegas, JSR | 1 |
| Asano, T; Hata, H; Kato, T; Kitamura, S; Maeda, T; Narahira, A; Nozaki, A; Shimizu, H; Watari, H; Yanagi, T | 1 |
| Krishnan, V; Mitragotri, S | 1 |
| Hide, M; Kan, T; Kawai, M; Matsubara, D; Takahagi, S; Tanaka, A | 1 |
| Ascierto, PA; Dréno, B; Flaherty, KT; Hauschild, A; Larkin, J; Lewis, KD; McArthur, GA; McKenna, E; Mun, Y; Ribas, A; Zhu, Q | 2 |
| Jobani, BM; Mohebi, E; Najafzadeh, N | 1 |
| Costa, L; Lobo-Martins, S; Mansinho, A; Pais, HL; Soares-de-Almeida, L; Teixeira de Sousa, R | 1 |
| Alencar, LMR; Alexis, F; da Silva de Barros, AO; Dahoumane, SA; de Oliveira Siqueira, LB; do Reis, SRR; Helal-Neto, E; Pinto, SR; Portilho, FL; Ricci-Junior, E; Santos-Oliveira, R | 1 |
| He, J; Huang, X; Sun, K; Teng, W; Tian, J; Yang, J; Zhan, X; Zhou, C; Zhou, L | 1 |
| Alexopoulos, LG; Charles, EM; Hellwig, CT; Rehm, M; Rožanc, J; Vetma, V | 1 |
| Beck, D; Bonin, M; Garbe, C; Kosnopfel, C; Krieg, K; Lasithiotakis, K; Meier, F; Niessner, H; Sinnberg, T; Wanke, I | 1 |
| Bassett, RL; Bedikian, AY; Cain, S; Homsi, J; Hwu, P; Hwu, WJ; Kim, DW; Kim, KB; Papadopoulos, NE; Patel, SP; Washington, E | 1 |
| Amson, R; Appel, MH; Basílio, AB; Boia-Ferreira, M; Chaim, OM; Da Costa, CRV; Hamasaki, AE; Matsubara, FH; Senff-Ribeiro, A; Telerman, A; Veiga, SS | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Kakizaki, A; Kambayashi, Y; Lyu, C; Sato, Y; Tanita, K | 1 |
| Ascierto, PA; Caro, I; Chang, I; Chapman, PB; Coleman, S; Dummer, R; Flaherty, KT; Haanen, JB; Hamid, O; Hauschild, A; Hogg, D; Larkin, J; Lorigan, PC; McArthur, GA; Ribas, A; Robert, C; Sosman, JA; Testori, A | 1 |
| Atkins, MB; Flaherty, LE; Kirkwood, JM; Moon, J; Othus, M; Ribas, A; Samlowski, WE; Sondak, VK; Witter, M | 1 |
| Anghel, RM; Haidar, A; Popescu, A | 1 |
| Caruntu, C; Constantin, C; Neagu, M; Surcel, M; Zurac, S | 1 |
| Cui, H; Huang, W; Li, X; Liao, X; Liu, X; Min, L; Shi, B; Sun, X; Xu, S; Yang, J; Zhang, M; Zheng, H; Zhu, Z | 1 |
| Ellis, J; Hertel, N; Johnson, H; Lee, D; Meng, Y; Morais, E; Philips, Z; Roskell, N; Walker, A | 1 |
| Ekielski, A; Iqbal, Z; Jaggi, M; Mishra, H; Mishra, PK; Talegaonkar, S | 1 |
| Altomonte, M; Bova, G; Calabrò, L; Camerini, R; Cisternino, F; Danielli, R; Di Giacomo, AM; Dragonetti, R; Giannarelli, D; Maio, M; Savelli, V | 1 |
| Arance, A; Ascierto, PA; Atkinson, V; Brady, B; Charles, J; Chiarion-Sileni, V; Cognetti, F; Di Giacomo, AM; Dutriaux, C; Gogas, H; Hassel, JC; Hernberg, MM; Jiang, J; Kalinka-Warzocha, E; Lebbé, C; Long, GV; Mauch, C; McNeil, C; Mihalcioiu, C; Mortier, L; Ny, L; Rizzo, J; Robert, C; Rutkowski, P; Saci, A; Savage, KJ; Schadendorf, D; Svane, IM | 1 |
| Assmann, CE; Bagatini, MD; da Cruz, IBM; de Andrade, CM; de Oliveira Alves, A; Mânica, A; Morsch, VMM; Palma, TV; Pelinson, LP; Pillat, MM; Schetinger, MRC; Stefanello, N; Ulrich, H; Weis, GCC | 1 |
| Beaugeard, L; Bonnet, A; Braconnier, E; da Silva Almeida, JRG; de Oliveira Júnior, RG; Ferraz, CAA; Grougnet, R; Groult, H; Picot, L; Prunier, G | 1 |
| Imano, M; Kawashima, K; Nishida, S; Obata, N; Satou, T; Tabata, M; Takeda, T; Tsubaki, M | 1 |
| Piotrowska, A; Rybarczyk, A; Slominski, AT; Tuckey, RC; Wierzbicka, J; Żmijewski, MA | 1 |
| Fukuhara, S; Izutsu, K; Miyagi-Maeshima, A; Morimura, S; Sugaya, M; Takahashi-Shishido, N; Tomita, Y | 1 |
| Corrêa, FM; Fernandes, RRA; Guerra, RL; Souza, MC; Zimmermann, IR | 1 |
| Harris, PJ; Ivy, SP; Luke, JJ; Rubinstein, LV; Smith, GL | 1 |
| Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH | 1 |
| Carlson, GW; Crocker, IR; Delman, KA; Khan, MK; Lawson, DH; Lowe, M; Marcus, DM; Maynard, N; Melton, A; Rizzo, M; Shelton, JW | 1 |
| Arance, A; Cantarini, M; Dummer, R; Gutzmer, R; Kim, KB; Liszkay, G; Lorigan, P; Middleton, MR; Nyakas, M; Robert, C; Schadendorf, D; Spencer, S | 1 |
| Armstrong, AW; Ma, C | 1 |
| Czyz, ME; Hartman, ML; Koprowska, K; Sztiller-Sikorska, M | 1 |
| Gibney, GT; Sondak, VK | 1 |
| Abdollahi, M; Nikfar, S; Teimouri, F | 1 |
| Chong, K; Hoon, DS; Huang, SK; Marzese, DM; Ohta, K; Sato, Y; Sim, MS | 1 |
| Agostinis, P; Govaere, O; Gremeaux, L; Maes, H; Roskams, T; Stas, M; Van den Broeck, A; van den Oord, JJ; Vankelecom, H; Wouters, J | 1 |
| Anderson, JE; Davis, JE; Kim, KB; Trinh, VA | 1 |
| Akiyama, M; Matsumoto, T; Nin-Asai, R; Saito, S; Sawada, M; Yokota, K | 1 |
| Bodell, MA; Kraus, ES; Lipson, EJ; Sharfman, WH | 1 |
| Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L | 1 |
| Bauer, J; Büttner, P; Eigentler, TK; Garbe, C; Keim, U; Leiter, U; Meckbach, D; Pflugfelder, A; Richter, S; Weide, B | 1 |
| Koon, HB; Megahed, AI | 1 |
| Kerr, J; Reyes, C; Satram-Hoang, S; Stepanski, EJ; Walker, MS | 1 |
| Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS | 1 |
| Bedikian, AY; Conry, R; Garbe, C; Grob, JJ; Lebbe, C | 1 |
| Barrera-Baena, P; Hervás-Molina, AJ; Jurado-García, J; Ruiz-Cuesta, P; Villar-Pastor, CM | 1 |
| Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M | 1 |
| Alrwas, A; Bassett, R; Bedikian, AY; Cain, S; Davies, MA; Deburr, TL; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Woodman, SE | 1 |
| Dubóczki, Z; Liszkay, G; Lóránd, A; Mészáros, P; Plótár, V; Vörös, A; Zs Tóth, E | 1 |
| Bedikian, AY; Carvajal, RD; Gordon, MS; Lewis, KD; Pavlick, AC; Rojas, PB; Schwartz, JD; Thompson, JA; Wolchok, JD; Wong, MK | 1 |
| Arozarena, I; Erice, O; Ferguson, J; Goicoechea, I; Margison, GP; Wellbrock, C | 1 |
| Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA | 1 |
| Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C | 1 |
| Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR | 1 |
| Augustine, CK; Beasley, GM; Dolber, PC; Mosca, PJ; Peterson, BL; Ross, M; Royal, R; Sharma, K; Speicher, P; Tyler, DS; Zager, JS | 1 |
| Apetoh, L; Bel, B; Dalac, S; Ghiringhelli, F; Hervieu, A; Jeudy, G; Mignot, G; Vabres, P | 1 |
| Bouchaab, H; Bucher, M; Gaide, O; Homicsko, K; Letovanec, I; Michielin, O; Peters, S; Zimmerman, S | 1 |
| Atanasov, G; Bartels, M; Hau, HM; Morgül, MH; Schmelzle, M; Schoenberg, MB; Seitz, AT; Simon, JC; Tautenhahn, HM; Uhlmann, D; Wiltberger, G | 1 |
| Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P | 1 |
| Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM | 1 |
| Armstrong, JL; Babatunde, F; Corazzari, M; Eleni Anagnostou, M; Hernandez-Tiedra, S; Hill, DS; Lopez-Valero, I; Lorente, M; Lovat, PE; McKee, CS; Redfern, CPF; Velasco, G | 1 |
| Faião-Flores, F; Fruet, AC; Maria, DA; Maria-Engler, SS; Pardi, PC; Quincoces Suarez, JA | 1 |
| Coco, P; Cocorocchio, E; Ferrucci, PF; Gandini, S; Minchella, I; Mosconi, M; Munzone, E; Pari, C; Passoni, C; Testori, A; Verrecchia, F | 1 |
| Gupta, K; Hardy, KM; Hendrix, MJ; Margaryan, NV; Murphy, GF; Scolyer, RA; Strizzi, L | 1 |
| Bilgi, O; Çelik, S; Emirzeoğlu, L; Karagöz, B; Özet, A; Özgün, A | 1 |
| Akhtar, S; Alhuraiji, A | 1 |
| Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V | 1 |
| Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM | 1 |
| Atkins, MB; Gibney, GT | 1 |
| Chiba, S; Fujishima, F; Hasegawa, Y; Ichinohasama, R; Ito, Y; Kurita, N; Kyogoku, C; Miyamoto, K; Nakamura, S; Obara, N; Ogawa, S; Sakata-Yanagimoto, M; Seki, M; Yokoyama, Y | 1 |
| Li, W; Mahato, RI; Mundra, V | 1 |
| Bird, TG; Child, F; Morris, SL; Wain, EM; Whittaker, S | 1 |
| Carlino, MS; Long, GV | 1 |
| Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS | 1 |
| Agarwala, SS; Bhatia, S; Brachmann, C; Brown, MP; Clawson, A; Conry, R; Del Vecchio, M; Elias, I; Ernst, S; Grob, JJ; Gutzmer, R; Hauschild, A; Haydon, A; Hersh, EM; Homsi, J; Karnoub, M; Kefford, R; Kendra, K; Li, M; Loquai, C; Renschler, MF; Robert, C; Testori, A | 1 |
| Bíró, T; Buzás, K; Endrész, V; Gyukity-Sebestyén, E; Harmati, M; Katona, RL; Kemény, L; Marton, A; Nagy, K; Németh, IB; Oláh, J; Tubak, V; Vígh, L; Vizler, C; Zvara, Á | 1 |
| Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R | 1 |
| Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M | 1 |
| Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W | 1 |
| Hou, XY; Huang, Q; Jiang, G; Tang, JQ; Xin, Y; Yang, M; Zhang, LZ; Zhang, P | 1 |
| Ding, B; Ding, X; Gao, S; Huang, X; Huang, Y; Wang, J; Wu, X; Xie, C; Xu, N; Zhan, S; Zhang, W; Zheng, Y | 1 |
| Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y | 1 |
| Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP | 1 |
| Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W | 1 |
| Dronca, RS; Ivanov, LV; Kottschade, LA; Leontovich, AA; Markovic, SN; Nevala, WK; Thompson, MA | 1 |
| Ling, B; Michel, D; Sakharkar, MK; Yang, J | 1 |
| Biteghe, FN; Davids, LM | 1 |
| Egorova, AV; Emelyanova, MA; Inshakov, AN; Khochenkov, DA; Nasedkina, TV; Ryabaya, OO; Stepanova, EV; Zasedatelev, AS | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z | 1 |
| Hata, H; Homma, S; Ichikawa, N; Imafuku, K; Kawamura, H; Kitamura, S; Miyazawa, H; Ohno, Y; Shimizu, H; Taketomi, A; Uehara, J; Yamaguchi, Y; Yanagi, T; Yoshida, T | 1 |
| Kudriavtsev, DV; Kudriavtseva, GT; Mardynskiĭ, IuS | 1 |
| Bedikian, AY; Hwu, P; Hwu, WJ; Johnson, MM; Kim, K; McIntyre, S; Papadopoulos, N; Warneke, CL | 1 |
| Ugurel, S | 1 |
| Bar-Eli, M; Lev, DC; Melnikova, VO; Villares, GJ; Zigler, M | 1 |
| Agarwala, SS; Gooding, WE; Kirkwood, JM; Moschos, S; Tarhini, AA | 1 |
| Artamonova, EV; Demidov, LV; Kharkevitch, GY; Manziuk, LV; Pirogova, NA | 1 |
| Ballo, MT; Bartell, HL; Bedikian, AY; Dett, TK; Hwu, P; Kim, KB; Myers, JN; Papadopoulos, NE | 1 |
| Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE | 1 |
| Bar, J; Catane, R; Gutman, H; Kutchuk, I; Schachter, J; Shapira-Frummer, R; Sulkes, A; Yerushalmi, R | 1 |
| Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M | 1 |
| Egberts, F; Hauschild, A; Hitschler, WN; Weichenthal, M | 1 |
| Dohmen-Scheufler, H; Guzel, A; Maciaczyk, J; Nikkhah, G; Ostertag, CB; Senturk, S; Volk, B | 1 |
| Becker, MR; Gaiser, T | 1 |
| Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
| Casadevall, A; Dadachova, E; Guimaraes, AJ; Howell, RC; Jongco, AM; Koba, W; Nosanchuk, JD; Revskaya, E; Sellers, RS | 1 |
| Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ | 1 |
| Agarwala, SS; Bedikian, AY; Eggermont, AM; Gilles, E; Itri, LM; Kay, R; Keilholz, U; Stein, CA; Suciu, S; Wu, J | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC | 1 |
| Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S | 1 |
| Marshall, E; O'Day, S; Redman, B; Trefzer, U; van den Eertwegh, AJ; Wagner, S; Weber, JS; Zarour, H | 1 |
| Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F | 1 |
| Cruz-Munoz, W; Kerbel, RS; Man, S | 1 |
| Collins, CM; Morgan, DS; Mosse, C; Sosman, J | 1 |
| Haratoh, R; Irie, R; Miyakawa, S; Tanese, K; Wakabayashi, A; Yamamoto, K | 1 |
| Mukesh, M; Murray, P; Shuttleworth, D | 1 |
| Amatruda, T; Anderson, CM; Atkins, MB; Boasberg, P; Gonzalez, R; Hersh, EM; Lutzky, J; O'Day, SJ; Thompson, JA; Wang, HJ; Weber, JS | 1 |
| Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA | 1 |
| Bracher, A; Loewe, R; Neumüller, K; Niederleithner, H; Pehamberger, H; Petzelbauer, P; Steele, S; Valero, T | 1 |
| Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
| Fuse, H; Imamura, Y; Nohara, T; Sakai, A | 1 |
| Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y | 1 |
| Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE | 1 |
| Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E | 1 |
| Gundersen, S; Hager, B; Jacobsen, KD; Tausjø, J | 1 |
| Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM | 1 |
| Bedikian, A; Buzoianu, M; Gonzalez, R; Hammershaimb, L; Hersey, P; Kirkwood, JM; Logan, T; O'Day, S; Richards, J; Sharfman, W; Sosman, J; Weber, R | 1 |
| Bae, SY; Baek, HJ; Han, DK; Hwang, TJ; Kook, H; Lee, JB; Lee, JK; Lee, MC; Lee, SY; Yun, SJ | 1 |
| Ballmer, A; Brady, B; Clingan, PR; Hersey, P; Kefford, RF; Morganti, A | 1 |
| Acland, K; Calonje, E; Harries, M; O'Doherty, M; Perez, A; Szyszko, T; Turajlic, S | 1 |
| Busch, C; Geisler, J; Knappskog, S; Lillehaug, JR; Lønning, PE | 1 |
| Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A | 1 |
| Busch, C; Geisler, J; Lillehaug, JR; Lønning, PE | 1 |
| Dorr, R; Gonzalez, R; Grenier, K; Hersh, E; O'Day, S; Ribas, A; Samlowski, WE; Sato, T; Stephenson, J; Weber, JS | 1 |
| Ihn, H; Inoue, Y; Ishihara, T; Kageshita, T; Kato, H | 1 |
| Bito, T; Ikeda, T; Nishigori, C; Nishitani, N; Tokura, Y | 1 |
| Augustine, CK; Osmond, GW; Padussis, J; Tyler, DS; Zipfel, PA | 1 |
| Davis, MD; Harlan, E; Pittelkow, MR | 1 |
| Doi, H; Iizuka, H; Ishida-Yamamto, A; Ito, Y; Tsuji, H | 1 |
| Drabick, JJ; Fateh, S; Gingrich, R; Neves, RI; Schell, TD | 1 |
| Davis, ME; Hsueh, T; Koya, RC; Ribas, A; Zuckerman, JE | 1 |
| Boasberg, P; Hamid, O; O'Day, S | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL | 1 |
| Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF | 1 |
| Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
| Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN | 1 |
| Abramov, ME; Artamonov, DN; Gorbacheva, LB; Tronov, VA | 1 |
| Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R | 1 |
| Algazi, AP; Cha, EN; Daud, AI; Soon, CW; Webb, EM | 1 |
| Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U | 1 |
| Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A | 1 |
| Abastado, JP; Audebourg, A; Avril, MF; Caignard, A; Garcette, M; Molina, TJ; Nardin, A; Prévost-Blondel, A; Tissier, F; Tow, C; Wong, WC | 1 |
| Caminal, JM; Fabra, A; Ferreres, JR; Marcoval, J; Penín, RM; Piulats, JM | 1 |
| Handler, MZ; Mruthyunjaya, P; Nelson, K | 1 |
| Tuma, RS | 1 |
| Boulinguez, S | 1 |
| Salameire, D | 1 |
| Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP | 1 |
| Chao, D; de Boer, CJ; Gonzalez, R; Gore, ME; Gutzmer, R; Hait, W; Ho, P; Lang, Z; Lawson, D; Loquai, C; Marshall, D; Mohr, P; O'Day, S; Ottensmeier, C; Pavlick, A; Richards, J; Schadendorf, D; Thompson, JA; Trefzer, U; Uhlar, C; Zhong, B | 1 |
| Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S | 1 |
| Abramov, ME; Artamonov, DN; Gorbacheva, LB; Lichinitser, MR; Tronov, VA | 1 |
| Kaneda, Y; Katayama, I; Kiyohara, E; Tamai, K | 1 |
| Berking, C; Flaig, MJ; Kunte, C; Roider, E; Ruzicka, T; Schneider, J | 1 |
| Abastado, JP; Avril, MF; Hong, M; Huang, C; Kato, M; Loumagne, L; Mackay, C; Nardin, A; Prévost-Blondel, A; Puaux, AL; Tow, C | 1 |
| Ding, B; Ding, X; Fan, W; Gao, J; Gao, S; Liu, J; Ma, L; Wu, X; Wu, Z; Xiang, W; Zhang, W; Zhu, Q | 1 |
| Drecoll, U; Garbe, C; Hauschild, A; Hofmann, MA; Kaatz, M; Mohr, P; Schadendorf, D; Tilgen, W; Trefzer, U; Ulrich, J; Weichenthal, M | 1 |
| Conte, H; Darrigade, AS; Ip Kan Fong, H; Jouary, T; Taïeb, A | 1 |
| Dzhabarov, FR; Nepomniashchaia, EM; Pozdniakova, VV; Rozenko, LIa | 1 |
| Aoude, LG; Bonazzi, VF; Brooks, BR; Brown, KM; Chow, D; Dutton-Regester, K; Ellis, JJ; Gartside, MG; Gibbs, R; Hayward, NK; Kobe, B; Lanagan, C; MacKeigan, JP; Muzny, D; Newsham, I; Niemi, NM; Palmer, JM; Pollak, T; Reid, J; Schmidt, CW; Sereduk, C; Stark, MS; Tang, N; Trent, J; Tyagi, S; Woods, SL; Wu, Y; Yin, H; Youngkin, D; Zismann, V | 1 |
| Abken, H; Bangard, C; Kurschat, P; Mauch, C; Schlaak, M; Schmidt, P | 1 |
| Queirolo, P; Spagnolo, F | 1 |
| Chong, JM; Okada, Y; Sakuranaka, H; Takimoto, M; Tanikawa, S | 1 |
| Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y | 1 |
| Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M | 1 |
| Annereau, JP; Chartrain, M; Gairin, JE; Gomes, B; Guilbaud, N; Lamant, L; Meyer, N; Riond, J; Stennevin, A; Vandenberghe, I | 1 |
| Abe, N; Irisawa, R; Kurashige, Y; Saito, M; Tsuboi, R | 1 |
| Becker, M; Gao, D; Gonzalez, R; Kounalakis, N; Lewis, K; McCarter, M; Pearlman, N; Poust, J; Robinson, W | 1 |
| Chen, Y; Dallaglio, K; Fujita, M; Gonzalez, R; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Thompson, DC; Vasiliou, V; Wang, J | 1 |
| Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E | 1 |
| Akiyama, S; Fukushige, T; Gunshin, K; Ikeda, R; Kanekura, T; Kawai, K; Matsushita, S; Okumura, H; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K | 1 |
| Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ | 1 |
| Gilbertson, RJ; Graham, TA | 1 |
| Apetoh, L; Bruchard, M; Chalmin, F; Ghiringhelli, F; Hervieu, A; Mignot, G; Rébé, C; Vabres, P; Végran, F | 1 |
| Abasq, C; Charles-Pétillon, F; Coat, C; De Braekeleer, M; Marcorelles, P; Quintin-Roué, I; Talagas, M; Uguen, A | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Bigner, DD; Friedman, HS; Gray, LA; Keir, ST; Reardon, DA | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Bichakjian, CK; Fox, MC; Frohm, ML; Johnson, TM; Lao, CD; Schwartz, JL | 1 |
| Han, F; Li, Z; Wang, P; Wang, Q; Wang, ZM; Xu, AE; Zheng, JH | 1 |
| Frank, S; Lotem, M; Merims, S; Ospovat, I; Peretz, T | 1 |
| Becker, JC; Paschen, A; Ugurel, S | 1 |
| Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M | 1 |
| Emmert, S; Helmbold, P; Kretschmer, L; Marsch, WC | 1 |
| Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Castel, T; Conill, C; Puig, S; Toscas, I | 1 |
| Agarwala, SS; Kirkwood, JM | 2 |
| Fujimoto, M; Hiraga, M; Kiyosawa, T; Murakami, T; Murata, S; Nakagawa, H; Ohtsuki, M | 1 |
| Acito, L; Bacchi, M; Beretta, M; Carlini, P; Cocconi, G; Di Sarra, S; Foladore, S; Gebbia, V; Maiello, E; Marchi, M; Passalacqua, R | 1 |
| Ake Hofer, P; Andersson, R; Henriksson, R; Riklund-Ahlström, K | 1 |
| Dréno, B; Wallon-Dumont, G | 1 |
| Batchelor, D; Boogerd, W; de Gast, GC; de Waal, MA; Kersten, MJ; Nieweg, OE; Nooijen, WJ; Sein, J; van de Kasteele, WF; Vyth-Dreese, FA | 1 |
| Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
| De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR | 1 |
| Günsberg, P; Jansen, B; Maierhofer, H; Monia, BP; Pehamberger, H; Polterauer, P; Selzer, E; Thallinger, C; Wacheck, V; Wolff, K; Wolschek, MF | 1 |
| Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M | 1 |
| Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N | 1 |
| Chiarion-Sileni, V; Corgna, E; Dalla Palma, M; De Salvo, GL; Del Bianco, P; Labianca, R; Lo Presti, G; Lo Re, G; Nortilli, R; Ridolfi, R; Romanini, A | 1 |
| Bernsen, MR; Gustafsson, B; Håkansson, A; Håkansson, L; Krysander, L; Rettrup, B; Ruiter, D | 1 |
| Akimov, MA; Barchuk, AS; Gel'fond, ML; Gershanovich, ML | 1 |
| Egyházi, S; Hansson, J; Kreklau, EL; Lindholm, C; Ma, S; Ringborg, U; Stierner, U; Ueno, T | 1 |
| Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ | 1 |
| Eisen, TG; Lens, MB | 1 |
| Jonas, DL; Kiebert, GM; Middleton, MR | 1 |
| Oubre, DN | 1 |
| Zelger, B; Zelger, BG | 1 |
| Busam, KJ; Chapman, P; Jungbluth, AA; Wolchok, J | 1 |
| Harkness, KA; Manford, MR | 1 |
| Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M | 1 |
| Eigentler, TK; Garbe, C | 1 |
| Agarwala, SS; Kirkwood, JM; Neuberg, D; Park, Y | 1 |
| Castel, T; Conill, C; González-Cao, M; Jorcano, S; Malvehy, J; Martí, R; Puig, S | 1 |
| Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R | 1 |
| Mitchell, MS | 1 |
| Ananthaswamy, HN; Bar-Eli, M; Lev, DC; McGary, EC; Melinkova, VO; Miller, C; Onn, A; Price, JE; Ruiz, M; Stone, V | 1 |
| Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J | 1 |
| Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N | 1 |
| Akimov, MA; Gershanovich, ML | 1 |
| Bayazit, YA; Camci, C; Erbagci, Z; Erkiliç, S; Koçer, NE | 1 |
| Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B | 1 |
| Bafaloukos, D; Bedikian, AY; Gogas, H | 1 |
| Négrier, S; Neidhardt-Bérard, EM | 1 |
| Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF | 1 |
| Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T | 1 |
| Ballardini, B; Bassi, F; De Pas, T; Gatti, G; Luini, A; Mauri, E | 1 |
| Hahka-Kemppinen, MH; Hernberg, MM; Pyrhönen, SO | 1 |
| Harting, MS; Kim, KB | 1 |
| Argon, A; Camlica, H; Duranyildiz, D; Oguz, H; Tas, F; Topuz, E; Yasasever, V | 1 |
| Buzaid, AC | 1 |
| Feun, L; Hurley, J; Marini, A; Mazumder, A; Moffat, F; Savaraj, N | 1 |
| Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD | 1 |
| Di Lauro, V; Freschi, A; La Mura, N; Nigri, P; Scalone, S; Veronesi, A; Zanetti, M | 1 |
| Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS | 1 |
| Jović, V; Konjević, G; Radomirović, V; Spuzić, I | 1 |
| Birner, P; Boehm, J; Heere-Ress, E; Hoeller, C; Jansen, B; Pehamberger, H; Thallinger, C; Wacheck, V; Wolff, K | 1 |
| Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C | 1 |
| Bonaccorsi, P; Borroni, RG; Bottoni, U; Calvieri, S; Clerico, R; Devirgiliis, V; Panasiti, V; Trasimeni, G | 1 |
| Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, JE; Malvehy, J; Martí, RM; Mellado, B; Puig, S; Sánchez, M | 1 |
| Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R | 1 |
| Alinari, L; Baccarani, M; Fina, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Eggermont, AM; Gore, M; Keilholz, U; Kleeberg, U; Kruit, W; Lehman, F; Lienard, D; Negrier, S; Patel, P; Proebstle, TM; Punt, CJ; Schadendorf, D; Schmittel, A; Suciu, S; Thomas, J; Velu, T | 1 |
| Amatruda, TT; Elashoff, RM; Gonzalez, R; Hoon, DS; Koyanagi, K; Lewis, K; O'Day, SJ; Robinson, WA; Takeuchi, H; Umetani, N; Wang, HJ | 1 |
| Sterry, W; Trefzer, U | 1 |
| Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J | 1 |
| Argon, A; Camlica, H; Tas, F; Topuz, E | 1 |
| Alpert, TE; Hatoum, GF; Morbidini-Gaffney, S; Sagerman, RH | 1 |
| Hoon, DS; Kitago, M; Koyanagi, K; Kuo, C; Martinez, SR; Milford, R; Mori, T; Nguyen, SL; O'Day, SJ; Takeshima, TL; Umetani, N; Vu, VD; Wang, HJ | 1 |
| Conway, BR; Suppasansatorn, P; Wang, G; Wang, W; Wang, Y | 1 |
| Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M | 1 |
| Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S | 1 |
| Archimbaud, A; Basset-Seguin, N; Dubertret, L; Guitera, P; Kerob, D; Levy, A; Ollivaud, L | 1 |
| Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y | 1 |
| Fukunaga, T; Kageshita, T; Kojima, S; Ogawa, H; Ono, T; Sakamoto, T; Soejima, H; Sugamura, K; Sugiyama, S; Tanoue, T; Yoshimura, M | 1 |
| Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD | 1 |
| Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS | 1 |
| Hansson, J | 1 |
| Bieber, T; Gollnick, H; Köhler, U; Linse, R; Luger, T; Schroth, K; Schubert, R; Stadler, R; Strannegård, O; Technau, K; Thoren, F; Vakilzadeh, F; Volkenandt, M; Von Eick, H | 1 |
| Barbaud, A; Schmutz, JL; Trechot, P | 1 |
| Amatruda, TT; Anderson, C; Baron, A; Becker, M; Dollarhide, S; Gonzalez, R; Lewis, KD; Matijevich, K; McCarter, M; O'Day, SJ; Pearlman, N; Robinson, WA; Zeng, C | 1 |
| Biasco, G; Casamassima, A; Chiarion-Sileni, V; Freschi, A; Galligioni, E; Guida, M; Nanni, O; Nortilli, R; Palma, MD; Picozzo, J; Ravaioli, A; Riccobon, A; Ridolfi, R; Romanini, A | 1 |
| Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G | 1 |
| Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M | 1 |
| Dadban, A; Daneshpazhooh, M; Raafat, J; Shokoohi, A | 1 |
| Andrews, S; Brem, S; Daud, AI; Ismail-Khan, R; Khan, MA; King, J; Munster, PN; Reintgen, DS; Sondak, VK | 1 |
| Bedikian, AY; Conry, R; DeConti, R; Gore, M; Haluska, FG; Hersey, P; Hersh, EM; Kirkwood, JM; Millward, M; Pavlick, AC; Pehamberger, H; Trefzer, U | 1 |
| Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G | 1 |
| Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D | 1 |
| Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T | 1 |
| Eggermont, AM; Gore, MA; Keilholz, U; Koller, J; Kruit, WH; Lienard, D; Patel, P; Punt, CJ; Suciu, S; Thomas, J | 1 |
| Cerny, T; Gillessen, S; Korte, W; Schlaeppi, MR; von Moos, R | 1 |
| Delaunay, M; Jouary, T; Taieb, A | 1 |
| Bauder-Wüst, U; Eisenhut, M; Eskerski, H; Haberkorn, U; Wolf, M | 1 |
| Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M | 1 |
| Becker, JC; Beiteke, U; Bröcker, EB; Durani, B; Jünger, M; Junghans, V; Kortüm, AK; Mauch, C; Remling, R; Schadendorf, D; Schulze, HJ; Terheyden, P | 1 |
| Hofmann, MA; Sterry, W; Trefzer, U | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S | 1 |
| Joukhadar, C; Kovar, FM; Poeppl, W; Pratscher, B; Quehenberger, P; Thallinger, C; Valent, P; Werzowa, J | 1 |
| Ascierto, PA; Casula, M; Cossu, A; Palmieri, G; Tanda, F | 1 |
| Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ | 1 |
| Conway, BR; Du, L; Nimmannit, U; Suppasansatorn, P; Wang, Y | 1 |
| Lau, TK; Li, RH; Mok, TS; Ng, PC; Tam, B; Tam, WH | 1 |
| Hesse, A; Mainka, A; Nettelbeck, DM; Quirin, C | 1 |
| Agarwala, SS; Cai, C; Gooding, WE; Kirkwood, JM; Tarhini, AA | 1 |
| Cashin, R; Corey-Lisle, PK; Einarson, TR; Hemels, M; Lui, P; Machado, M | 1 |
| Adema, AD; Bhakat, KK; Boven, E; Fontijn, D; Peters, GJ; Pinedo, HM | 1 |
| Stein, CA | 1 |
| Bayer, W; Heim, A; Hoffmann, D; Nettelbeck, DM; Potthoff, A; Wildner, O | 1 |
| Jelić, S; Jović, V; Konjević, G; Radulović, S; Spuzić, I; Vuletić, A | 1 |
| Bajetta, E | 1 |
| Bhawan, J; Demierre, MF; Karakis, I; McGeeney, B; Thiele, JJ; Wolpowitz, D | 1 |
| Brocard, A; Dréno, B; Quéreux, G | 1 |
| Becker, JC; Beyeler, M; Bröcker, EB; Dummer, R; Garbe, C; Gille, J; Hauschild, A; Kaehler, KC; Kaufmann, R; Leiter, U; Pföhler, C; Schadendorf, D; Spieth, K; Tilgen, W; Ugurel, S | 1 |
| Baba, H; Imamura, Y; Inukai, T; Kobayashi, S; Nakajima, H; Noriki, S; Orwotho, N; Uchida, K; Yayama, T | 1 |
| Dummer, R; Eigentler, T; Ellwanger, U; Garbe, C; Gutzmer, R; Hauschild, A; Linse, R; Radny, P; Stadler, R; Ulrich, J; Weichenthal, M | 1 |
| Camacho, L; Gupta, R; Hoos, A; Kirkwood, JM; Lutzky, J; Mann, GB; Parmiani, G; Richards, J; Srivastava, PK; Testori, A; Tosti, G; Whitman, E; Yuh, L | 1 |
| Neff, WJ; Nystrom, KK; Pick, AM | 1 |
| Herrmann, R; Hess, V; Schwabe, M; Veelken, H | 1 |
| Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC | 1 |
| Bael, TE; Gollob, JA; Peterson, BL | 1 |
| Dutz, JP; Najar, HM | 1 |
| Schuh, T; Siedek, V; Wollenberg, A | 1 |
| Brell, J; Dehart, WK; Gilliam, AC; Lu, KQ | 1 |
| Czarnetzki, BM; Macher, E | 1 |
| Thiers, BH | 1 |
| Khan, MS; Ross, WM | 1 |
| Kennealey, GT; Kirkwood, JM; Luikart, SD | 1 |
| Balch, CM; Hersey, P | 1 |
| Bychkov, MB; Perevodchikova, NI | 1 |
| Galle, K; Schweiss, D | 1 |
| Al-Sarraf, M; Balcerzak, SP; Costanzi, JJ; Eyre, HJ; Fletcher, WS; Frank, J; O'Bryan, RM; Taylor, S | 1 |
| Hill, GJ; Hill, HZ; Krementz, ET | 1 |
| Balch, CM; Bartolucci, AA; Murray, D; Presant, C | 1 |
| Aigner, KR; Börger, G; Illig, L; Jungbluth, A; Link, KH; Müller, H; Ringenberg, T; Ruppel, R; Schwemmle, K; Walther, H | 1 |
| Angelini, G; Bonifazi, E; Meneghini, CL | 1 |
| Jimbow, K; Kawamura, M; Maeda, K; Miura, S | 1 |
| Bernengo, MG; Fra, P; Lisa, F; Meregalli, M; Zina, G | 1 |
| Bertelsen, CA; Kaiser, LR; Kern, DH; Korn, EL; Mann, BD; Morton, DL; Storm, FK | 1 |
| Ingvar, C; Jönsson, PE; Stridbeck, H | 1 |
| Calbo, L; Gorgone, S; Melita, P; Palmeri, R; Salibra, M | 1 |
| Aigner, K; Henneking, K; Hild, P; Hundeiker, M; Paul, E | 1 |
| Ariyan, S; Kirkwood, JM; Mitchell, MS | 1 |
| Hayasaka, K; Ikeda, S; Ishihara, K; Jimbow, K; Kukita, A; Seki, Y; Suzuki, M; Terakado, T | 1 |
| Klemm-Mayer, H; Rasokat, H; Wagner, G | 1 |
| Hori, Y; Kawashima, M; Kukita, A; Mizoguchi, M; Shimada, S; Watanabe, S; Yamada, K | 2 |
| Ichihashi, M; Inoi, T; Mishima, Y; Mojamdar, M | 1 |
| Féaux de Lacroix, W; Pullmann, H; Runne, U | 1 |
| Doepfmer, K; Féaux de Lacroix, W; Groth, W; Hauk, H; Runne, U; Wacker, D | 1 |
| Aigner, K; Hild, P; Hundeiker, M | 1 |
| Ding, YA; Hwang, WS; Lee, WC; Leu, FJ | 1 |
| Haruyama, H; Ijichi, H; Isemura, T; Nakagawa, M; Nakanishi, S; Okano, R; Sawada, S; Shimazaki, C; Tsuji, H; Ueda, K | 1 |
| Aiba, K; Domyo, M; Ezaki, K; Horikoshi, N; Inagaki, J; Inoue, K; Miyamoto, H; Nagata, T; Ogawa, M | 1 |
| Antz, H; Doepfmer, K; FEAUX DE Lacroix, W; Groth, W; Runne, U | 1 |
| Bolton, PM; Clunie, GJ; Dury, M; Furnival, CM; Gough, IR | 1 |
| Borisov, AI; Kogoniia, LM; Moroz, LV; Perevodchikova, NI; Platinskiĭ, LV | 1 |
| Fletcher, WS; Golomb, FM; Grage, TB; Hill, GJ; Krementz, ET; Minton, JP; Moss, SE | 1 |
| Balch, C; Bartolucci, AA; Presant, CA; Troner, M | 1 |
| Greco, FA; Knost, JA; Oldham, RK; Reynolds, V | 1 |
| Al-Sarraf, M; Bottomley, R; Costanzi, JJ; Dixon, D; Fabian, C; Groppe, C; Neidhart, J | 1 |
| Chiba, M; Homma, K; Jimbow, K; Kizukuri, K | 1 |
| Adamus, J; Aubert, C; Bajetta, E; Beretta, G; Bonadonna, G; Bufalino, R; Cascinelli, N; Cocconi, G; De Marsillac, J; Durand, J; Ikonopisov, RL; Kiss, B; Lejeune, F; MacKie, R; Madej, G; Mechl, Z; Milton, GW; Morabito, A; Mulder, H; Paul, E; Peter, H; Priario, J; Rumke, P; Sertoli, R; Tomin, R; Veronesi, U | 1 |
| Arlen, M; Cohen, M; Hollinshead, A; Kundin, WD; Scherrer, J; Tanner, K; Yonemoto, R | 1 |
| Muth, M; Pullmann, H | 1 |
| Altenähr, E; Doering, C; Orfanos, CE; Pickartz, H | 1 |
| Hayasaka, K; Ikeda, S; Ishihara, K; Jimbow, K; Kukita, A; Seki, Y; Takahashi, H; Terakado, T | 1 |
| Caselitz, J; Jänner, M; Voigt, H | 1 |
| Crone-Münzebrock, W; Kröger, E; Stritzke, P; Voigt, H | 1 |
| Lorincz, AL; Winston, EM; Yung, CW | 1 |
| Adamczyk, B; Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
| Blackledge, G; Crowther, D; Palmer, MK; Thatcher, N | 1 |
| Gordy, DD; Murray, JL; Robertson, DM; Wilkinson, CP | 1 |
| Aass, N; Fodstad, O; Pihl, A | 1 |
| Kollakowski, M; Kunze, J; Roeber, H | 1 |
| Bolling, R; Meyer-Hamme, S; Schauder, S | 1 |
| Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N | 1 |
| Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M | 1 |
| Gröhn, P; Korpela, M; Kumpulainen, E; Vuoristo, M | 1 |
| Asko-Seljavaara, S; Hahka-Kemppinen, M; Jekunen, A; Muhonen, T; Pyrhönen, S; Virolainen, M | 1 |
| Kishimoto, S; Ueda, E; Yasuno, H | 1 |
| Gillen, P; Keane, FB; Kerin, MJ; Monson, JR; Tanner, WA; Wilkie, J | 1 |
| Brossart, P; Hunstein, W; Keilholz, U; Möhler, T; Scheibenbogen, C; Tilgen, W | 1 |
| Atzpodien, J; Chaitchik, S; Duensing, S; Franzke, A; Kirchner, H; Körfer, A; Lopez Hänninen, E; Poliwoda, H; Schomburg, A; Volkenandt, M | 1 |
| Asano, K; Ishihara, K; Yamazaki, N | 1 |
| Ameglio, F; Carpano, S; Cavaliere, R; Di Lauro, L; Frasca, AM; Lopez, M; Pignatti, F; Rosselli, M; Vici, P; Vitelli, G | 1 |
| Becker, JC; Burg, G; Dieleman, JP; Dummer, R; Gore, ME; Grobben, HC; Guillou, PJ; Hancock, BW; Oskam, R | 1 |
| Balch, CM; Benjamin, RS; Buzaid, A; el-Naggar, AK; Legha, SS; Papadopoulos, NE; Plager, C; Ring, S; Ross, M | 1 |
| Korovin, SI; Tolstopiatov, BA | 2 |
| Bootz, F; Breuninger, H; Lindstedt-Hilden, M | 1 |
| Bos, G; Brown, D; Fletcher, WS; Lebredo, L; Moseley, HS; Small, K; Woltering, EA | 1 |
| Ferrone, S; Imai, K; Kageshita, T; Kimura, T; Kuriya, N; Ono, T; Tsujisaki, M; Yoshii, A | 1 |
| Goitsuka, R; Goto, N; Hasegawa, A; Momoi, Y; Ono, K; Shimada, T; Tsujimoto, H; Uno, Y; Watari, T | 1 |
| Bajetta, E; Barduagni, M; Bernengo, MG; Comella, G; Di Leo, A; Giannotti, B; Queirolo, P; Sertoli, MR; Tribbia, G; Zampino, MG | 1 |
| Bureau, B; Célérier, P; Dreno, B; Litoux, P | 1 |
| Masuzawa, M | 1 |
| Christophers, E; Clausen, M; Hauschild, A; Osterkamp, G | 1 |
| Chaitchik, S; Gutman, M; Inbar, MJ; Merimsky, O; Ron, IG | 1 |
| Baba, N; Ichiyama, S; Matsuzaki, T; Miyagawa, K; Miyazawa, M; Nagatani, T; Nakajima, H; Onuma, R; Uchiyama, M | 1 |
| Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B | 1 |
| Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL | 1 |
| Atzpodien, J; Kirchner, HH; Poliwoda, H | 1 |
| Anderson, CM; Buzaid, AC; Legha, SS | 1 |
| Cavillon, C; Claude, R; Desplechain, C; Egloff, H; Franck, F; Goujon, N; Lautier, A; Plagne, R; Rigondet, G; Sale, JM | 1 |
| Hauschild, A | 1 |
| Rudolf, Z; Strojan, P | 2 |
| Bedikian, A; Buzaid, AC; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S | 1 |
| Ang, PT; Tan, EH | 1 |
| Chapman, PB; Houghton, AN; Meyers, ML | 1 |
| Saida, T | 1 |
| Egyházi, S; Hansson, J; Margison, GP; Ringborg, U | 1 |
| Ariyan, S; Bolognia, J; Poo, WJ | 1 |
| Legha, SS | 1 |
| Fefer, A; Gold, PJ; Thompson, JA | 1 |
| de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G | 1 |
| Burg, G; Dummer, R; Flace, A; Meyer, JC; Seifert, B; Wimmer, I | 1 |
| Dekio, S; Hayashi, S; Ohno, T; Takata, Y | 1 |
| Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG | 1 |
| Hart, AA; Israels, SP; Kroon, BB; Nieweg, OE; Rümke, P; Strobbe, LJ | 1 |
| Flaherty, LE; Fletcher, WS; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Walker, MJ; Weiss, GR | 1 |
| Enk, AH; Knop, J; Nashan, D | 1 |
| Becker, JC; Bröcker, EB; Kämpgen, E; Schwaaf, A; Trcka, J | 1 |
| Ariyan, S; Poo, WJ | 1 |
| Calista, D; Landi, C; Schianchi, S | 1 |
| Punt, CJ | 1 |
| Akande, N; Ali-Osman, F; Bedikian, A; Benjamin, RS; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C | 1 |
| Ali-Osman, F; Anderson, CM; Bedikian, A; Braunschweiger, PG; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C; Sussman, J | 1 |
| Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H | 1 |
| Egorova, NI; Garin, AM; Gorozhanskaia, EG; Koroleva, EIu; Kushlinskiĭ, NE; Larionova, VB | 1 |
| Bénard, J | 1 |
| Aoki, K; Hayashi, O; Nishioka, K; Ohara, H; Tanaka, K; Umeda, T; Yokoyama, A | 1 |
| Aamdal, S; Andersson, R; Bjelkengren, G; Ingvar, C; Jungnelius, U; Karlsson, M; Malmström, P; Mattsson, J; Ringborg, U; Stierner, U; Westberg, R; Willman, K; Wist, E | 1 |
| Bedikian, A; Benjamin, R; Buzaid, AC; Colome, M; Eton, O; Lee, JE; Lee, JJ; Legha, SS; Mansfield, P; Papadopoulos, N; Plager, C; Rice, J; Ring, S; Ross, M; Strom, E | 1 |
| Fuchs, T; Keilholz, U; Proebstle, TM; Scheibenbogen, C; Sterry, W | 1 |
| Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M | 1 |
| Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K | 1 |
| Castro, MP; Legha, S; Spencer-Cisek, P; Sponzo, RW; VanAuken, J | 1 |
| Jedrzejczak, WW | 1 |
| Ishikawa, M; Wada, T; Yamamoto, A; Yamazaki, N | 1 |
| Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM | 1 |
| Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM | 1 |
| Boasberg, PD; Cannon, M; Edwards, S; Essner, R; Fawzy, NW; Foshag, LJ; Fournier, P; Gammon, G; Guo, M; Johnson, TD; Kristedja, TS; Martin, MA; Morton, DL; O'Day, SJ; Stern, S; Weisberg, M | 1 |
| Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Bedikian, A; Benjamin, RS; Buzaid, AC; Carrasco, CH; East, M; Eton, O; Gianan, M; Hodges, C; Legha, SS; Papadopoulos, N | 1 |
| Boeynaems, JM; Duhant, X; Ghanem, G; Jacquemotte, F; Kinnaert, E; Morandini, R | 1 |
| Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC | 1 |
| Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N | 1 |
| Agarwala, S; Hillner, BE; Middleton, MR | 1 |
| Kageshita, T; Kuribayashi, N; Ono, T | 1 |
| Cohen, MH; Johnson, JR; Middleton, MR | 1 |
| Eggermont, AM; Keilholz, U; Suciu, S | 1 |
| Egorov, GN; Gorbonova, VA; Orel, NF; Perevodchikova, NI | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Klimek, VM; Wolchok, JD | 1 |
| Deraemaecker, R; Sales, F; Vandeweyer, E | 1 |
| Christophers, E; Hauschild, A; Lischner, S | 1 |
| A'Hern, RP; Ayliffe, MJ; Eisen, T; Gore, ME; Hill, ME; Johnston, SR; Moore, J; Riches, PG; Thomas, JM; Vaughan, MM | 1 |
| Goos, M; Hillen, U; Willers, C | 1 |
| Kroon, BB; Nieweg, OE | 1 |
| Heere-Ress, E; Hoeller, C; Hoermann, M; Hollenstein, U; Jansen, B; Lucas, T; Pehamberger, H; Schlagbauer-Wadl, H; Wacheck, V; Wolff, K | 1 |
| Kretschmer, L; Marsch, WC; Neumann, C; Preusser, KP | 1 |
| Church, C; DePriest, CB; Dillman, RO; Dobbs, TW; Ruben, RH; Schulof, R; Soori, G; Wiemann, MC | 1 |
| Caubet, JF; Huncharek, M; McGarry, R | 1 |
| Franke, W; Neumann, NJ; Ruzicka, T; Schulte, KW | 1 |
| Kamanabrou, D | 1 |
| Burg, G; Dummer, R | 1 |
| Gore, M; Stebbing, J; Thomas, M | 1 |
| Biasco, G; Casadei, S; Pantaleo, MA | 1 |
| Chan, C; O'Day, J | 1 |
| Dzodić, R; Jelić, S; Jović, V; Konjević, G; Radulović, S; Spuzić, I | 1 |
| Heere-Ress, E; Jansen, B; Joukhadar, C; Klein, N; Mader, RM; Müller, M; Pehamberger, H; Rizovski, B; Schrolnberger, C; Strauchmann, N | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Kennedy, RD; McAleer, JJ | 1 |
| Burton, A; Dunn, JA; Goodman, A; Marsden, J; Young, AM | 1 |
| Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D | 1 |
| Amicucci, G; Deraco, M; Fiorentini, G; Guadagni, S; Miotto, D; Palumbo, G; Pilati, PL; Rossi, CR; Russo, F; Santinami, M; Valenti, M | 1 |
| Atzpodien, J; Bröcker, EB; Fluck, M; Kamanabrou, D; Müller, I; Neuber, K; Neumann, C; Patzelt, T; Paul, E; Reitz, M; Rünger, TM; Schuler, G; von den Driesch, P | 1 |
| Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P | 1 |
| Anderson, C; Becker, M; Gatlin, K; Gibbs, P; Gonzalez, R; LaClaire, S; O'Driscoll, M; Pearlman, N; Stephens, J | 1 |
| Babović, N; Jelić, S; Kreacić, M; Matković, S; Popov, I; Stamatović, L | 1 |
| Schadendorf, D | 1 |
| Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G | 1 |
| Dedkov, AG; Korovin, SI; Medinets, IuR; Palivets, AIu; Protsenko, VV; Smakova, MS; Tolstopiatov, BA | 1 |
| Bernard-Marty, C; Khayat, D; Meric, JB; Rixe, O | 1 |
| Feun, LG; Hurley, J; Marini, A; Savaraj, N | 1 |
| Campos, LT; Lanzotti, VJ; Samuels, ML; Sinkovics, JG | 1 |
| Salem, PA | 1 |
| Baker, LH; Izbicki, RM; Ratanatharathorn, V; Samson, MK | 1 |
| Zaumseil, RP | 1 |
| Agrup, G; Hafström, L; Jönsson, PE; Rorsman, H | 1 |
| Goodnight, JE; Morton, DL | 1 |
| Benjamin, RS | 1 |
| Gutterman, JU; Hersh, EM; McBride, CM | 1 |
| Hill, GJ; Hill, HZ; Szramowski, J | 1 |
| Berger, JL; Friedman, M; Holyoke, ED; Karakousis, CP; Lopez, R; Takita, H | 1 |
| Jassem, J; Kopacz, A; Wojszwiłło-Geppert, E | 1 |
| Kolarić, K; Malenica, B; Roth, A | 1 |
| Hagedorn, M; Meuret, G; Schmitt, E; Waldermann, F | 1 |
| Czarnetzki, BM; Frosch, PJ; Gottschalk, I; Grundmann, E; Macher, E | 1 |
| Fiedler, H; Lübbe, D; Zaumseil, RP | 1 |
| Crispen, R; Das Gupta, TK; El-Domeiri, AA; Sabet, TY; Simo, C; Trippon, M | 1 |
| Carey, RW; Cosimi, AB; Kaufman, SD; Wood, WC | 1 |
| Hall, SW; Loo, TL | 1 |
| Banzet, P; Chastang, C; Civatte, J; Cottenot, F; Israel, L; Jacquillat, C; Maral, J; Puissant, A | 1 |
| Block, JB; Drakes, TP; Isacoff, W; Tabbarah, H | 1 |
| Carbone, PP; Costello, W | 1 |
| Azzarelli, A; Bajetta, E; Beretta, G; Bonadonna, G; De Lena, M; Tancini, G; Veronesi, U | 1 |
| Kleeberg, UR | 1 |
| Bodurtha, A; Ghose, T; Guclu, A; MacDonald, AS; Norvell, ST; Tai, J | 1 |
| Davis, JM; Mitchell, MS; Mokyr, MB | 1 |
| Aranha, GV; Grage, TB | 1 |
| Currie, GA; Hedley, DW; McElwain, TJ | 1 |
| Duchková, H; Kubíková, M; Richter, J; Rus, J | 1 |
| Carmo-Pereira, J; Oliveira Costa, F; Pimentel, P | 1 |
| Currie, GA; McElwain, TJ | 1 |
| Banzet, P; Dufourmentel, C; Jacquillat, C; Ricbourg, B | 1 |
| Falkson, G; Van Dyk, JJ | 1 |
| Luce, JK | 1 |
| Andersson, T | 1 |
| Kleeberg, UR; Schreml, W | 1 |
| Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O | 1 |
| Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D | 1 |
| Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K | 1 |
| Crowther, D; Lee, SM; Margison, GP; Thatcher, N | 1 |
| Maclennan, KA; Okon, E; Polliack, A; Shiloni, E | 1 |
| Guillou, PJ; Reynolds, JV; Somers, SS | 1 |
| Esteguy, M; Leiguarda, R; Merello, M; Perazzo, F | 1 |
| Buzaid, AC; Murren, J | 1 |
| Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE | 1 |
| Fiedler, H; Hetschko, I; Lübbe, D; Taube, KM; Wohlrab, W; Wozniak, KD | 1 |
| Agnifili, A; Carboni, M; D'Amore, L; Gianfelice, F; Giuliani, M; Gossetti, F; Negro, P | 1 |
| Breistøl, K; Fodstad, O; Kjønniksen, I | 1 |
| Burg, G; Dummer, R; Eilles, C; Miller, K | 1 |
| Castel, T; Castro, J; Daniels, M; Estapé, J; Gratacós, R; Grau, JJ; Mascaró, JM; Palou, J; Vilalta, A; Viñolas, N | 1 |
| Baker, AR; Barth, RJ; Venzon, DJ | 1 |
| Bajorin, DF; Chapman, PB; Cody-Johnson, BV; Heelan, RT; Lovett, DR; Oettgen, HF; Portlock, CS; Steffens, TA; Templeton, MA; Wong, GY | 1 |
| Buzaid, AC; Durivage, HJ; Murren, JR | 1 |
| Richards, JM | 1 |
| Ho, VC; Sober, AJ | 1 |
| Bajetta, E; Bernengo, MG; Brogelli, L; Brunetti, I; Giannotti, B; Maifredi, G; Negretti, E; Sertoli, MR; Sofra, MC; Zumiani, G | 1 |
| Daly, A; Drumm, JE; Harkin, KP; O'Brien, P | 1 |
| Colombel, F; Le Franc, P; Leroy, B; Scherpereel, P; Thomas, P | 1 |
| Ikegawa, S; Ishihara, K | 1 |
| Balch, CM | 1 |
| Ishihara, K | 2 |
| Barnekow, A; Paul, E; Schartl, M | 1 |
| Ballin, R; Klöppel, R; Lommatzsch, PK | 1 |
| Avril, MF | 1 |
| Atkinson, WE; Bucolo, AP; Farley, H; Guin, JD; Langston, HD; Prather, JL | 1 |
| Cartei, G; Ceschia, T; Clocchiatti, L; Fasola, G; Galletti, D; Marsilio, P; Morandini, G; Sibau, A | 1 |
| English, JS; Lever, RS; MacKie, RM; Young, DW | 1 |
| Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D | 1 |
| Eksborg, S; Ingvar, C; Jönsson, PE; Stigsson, L | 1 |
| Alevizakos, N; Athanassiou, A; Bafaloukos, D; Barbounis, V; Dimitriadis, M; Pectasides, D; Varthalitis, J; Yianniotis, H | 1 |
| Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD | 1 |
| Ambrosini, G; Amichetti, M; Piazza, M; Piffer, S; Valdagni, R | 1 |
| Klimek, M; Pawlicki, M | 1 |
| Burgess, M; Pasterz, R; Savaraj, N | 1 |
| Milbradt, R; Neubert, J; Schneider, E | 1 |
| Martz, G; Stahel, RA | 1 |
| Abe, H; Doi, S; Murai, H; Sawamura, Y; Tashiro, K | 1 |
| Böckers, M; Bork, K; Keller, E | 1 |
| Bella, M; Bocchi, P; Ceci, G; Cocconi, G; Gabrielli, M; Melissari, M | 1 |
| Konz, B; Korting, HC; Strasser, S | 1 |
| de Garis, ST; Dische, S; Nelstrop, A; Rustin, GJ | 1 |
| Garbe, C; Guenther-Eymann, K; Orfanos, CE; Stadler, R | 1 |
| Allegra, JC; Richman, SP; Seeger, J | 1 |
| Banerjee, SS; Craig, P; Gleave, N; Mene, A; Orton, C; Thatcher, N | 1 |
| Kogonia, LM; Moros, LW; Perevodchikova, NJ | 1 |
| Biltz, H; Budde, U; Fiedler, U; Harbrecht, U; Kreysel, HW | 1 |
| Belli, F; Cascinelli, N; Marolda, R; Prada, A; Santinami, M; Vaglini, M | 1 |
| Kogoniia, LM; Manziuk, LV; Marenich, AF; Osmanov, DSh; Roshchin, EM | 1 |
| Abdi, EA; Hanson, J; McPherson, TA | 1 |
| Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
| Carey, RW; Kunz, VS | 1 |
| Carmo-Pereira, J; Costa, FO; Henriques, E | 1 |
| Dobrek, Z | 1 |
| Boddie, AW; Cangir, A | 1 |
| Anderson, H; Craig, P; Davenport, P; James, R; Thatcher, N | 1 |
| Falkson, G; Sarli, R; Vorobiof, DA | 1 |
| Gundersen, S; Hager, B; Tausjø, J | 2 |
| Garbe, C; Orfanos, CE; Stadler, R | 1 |
| Braun-Falco, O; Hölzel, D; Konz, B; Landthaler, M; Schmoeckel, C | 1 |
| Karakousis, CP | 1 |
| Chessa, A; Desogus, A; Floris, C; Muggiano, A; Sulis, E; Tedde, A; Turno, R | 1 |
| Koh, H | 1 |
| Clark, WH; Elder, D; Goldman, LI; Mastrangelo, MJ; Stennett, J | 1 |
| Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS | 1 |
| Case, LD; Cooper, MR; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; Sterchi, JM; Stuart, JJ; Wells, HB; White, DR | 1 |
| Hansson, J; Lagerlöf, B; Ringborg, U; Strander, H | 1 |
| Hypa, F; Leyh, F; Weber, M; Winzer, M | 1 |
| Chuang, VP; Frost, DB; Mavligit, G; Patt, YZ; Wallace, S | 1 |
60 review(s) available for dacarbazine and Skin Neoplasms
| Article | Year |
|---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Nanotechnology approaches in the current therapy of skin cancer.
Topics: Administration, Cutaneous; Antineoplastic Agents; Dacarbazine; Drug Carriers; Drug Resistance, Neoplasm; Fluorouracil; Gold; Humans; Melanoma; Metal Nanoparticles; Nanoparticles; Nanotechnology; Particle Size; Skin Absorption; Skin Neoplasms; Skin Physiological Phenomena; Surface Properties | 2020 |
Nanoparticles for topical drug delivery: Potential for skin cancer treatment.
Topics: Administration, Cutaneous; Antineoplastic Agents; Dacarbazine; Drug Carriers; Fluorouracil; Gold; Humans; Metal Nanoparticles; Nanoparticles; Skin Absorption; Skin Neoplasms; Skin Physiological Phenomena | 2020 |
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Melanoma; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Vemurafenib | 2020 |
Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Humans; Interferons; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Metastasis; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Vemurafenib | 2018 |
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Melanoma; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome | 2013 |
Dabrafenib therapy for advanced melanoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; Melanoma; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; Imidazoles; Indoles; Interferon-alpha; Interleukin-2; Ipilimumab; Melanoma; Oximes; Platinum Compounds; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides; Taxoids; Temozolomide; Vemurafenib | 2014 |
Nanoparticle-mediated drug delivery for treating melanoma.
Topics: Antineoplastic Agents; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanoparticles; Skin Neoplasms | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; Quality of Life; Skin Neoplasms; Temozolomide; Treatment Outcome | 2015 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Surgical Procedures; Humans; Imidazoles; Indoles; Ipilimumab; Lymph Node Excision; Melanoma; Neoplasm Staging; Nivolumab; Oximes; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Skin Neoplasms; Sulfonamides; Switzerland; Temozolomide; Vemurafenib | 2016 |
Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Immunologic Factors; Interferon-alpha; Melanoma; Melanoma, Cutaneous Malignant; Remission Induction; Skin Neoplasms; Treatment Outcome | 2016 |
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Survival Rate; Uveal Neoplasms; Vinblastine | 2008 |
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; CD146 Antigen; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Immunotherapy; Interleukin-8; Melanoma; Neoplasm Metastasis; Skin Neoplasms | 2008 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2009 |
Primary cutaneous Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vinblastine | 2009 |
[Metastatic malignant melanoma of the urinary bladder: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-beta; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Urinary Bladder Neoplasms; Vincristine | 2009 |
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Humans; Ipilimumab; Melanoma; Skin Neoplasms | 2010 |
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Silencing; Genetic Therapy; Glioma; Humans; Melanoma; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2011 |
Upcoming strategies for the treatment of metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Ipilimumab; MAP Kinase Kinase Kinases; Melanoma; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sulfonamides; Vemurafenib | 2012 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2013 |
[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Dacarbazine; Drug Approval; Drug Monitoring; Humans; Immunotherapy; Ipilimumab; Melanoma; Pharmacovigilance; Proportional Hazards Models; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2012 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors | 2003 |
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vincristine | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine | 2004 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Tamoxifen; Taxoids; Temozolomide; Treatment Outcome | 2004 |
[Disseminated melanoma treatment].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Prognosis; Skin Neoplasms | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Temozolomide; Thionucleotides; Treatment Outcome | 2004 |
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms | 2007 |
Immunotherapy of malignant melanoma.
Topics: Antigens, Neoplasm; BCG Vaccine; Cholera Vaccines; Clinical Trials as Topic; Dacarbazine; Dinitrochlorobenzene; Double-Blind Method; Humans; Immunotherapy; Interferons; Levamisole; Melanoma; Random Allocation; Skin Neoplasms; Skin Tests; Transfer Factor | 1982 |
Current status and future prospects for adjuvant therapy of melanoma.
Topics: Antigens, Neoplasm; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interferons; Interleukin-2; Melanoma; Skin Neoplasms; T-Lymphocytes, Regulatory | 1984 |
[Chemotherapy for the treatment of angiosarcoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Doxorubicin; Female; Hemangioendothelioma; Hemangiosarcoma; Humans; Male; Skin Neoplasms; Vincristine | 1993 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 1995 |
Medical treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Survival Analysis; Treatment Outcome | 1996 |
[Treatment of malignant melanoma: recent advances and perspectives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nimustine; Skin Neoplasms; Tamoxifen; Vincristine | 1997 |
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1997 |
The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
Topics: Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interferon-gamma; Interleukin-2; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms | 1998 |
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Calcium; Cisplatin; Creatinine; Dacarbazine; Fatal Outcome; Humans; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Phosphorus; Skin Neoplasms; Tumor Lysis Syndrome; Uric Acid; Vinblastine | 1999 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2000 |
Systemic chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Melanoma; Neoadjuvant Therapy; Palliative Care; Remission Induction; Skin Neoplasms; Survival Rate | 2000 |
[Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Head and Neck Neoplasms; Humans; Interferons; Lymph Node Excision; Melanoma; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tumor Cells, Cultured | 2000 |
Melanoma erysipeloides: successful treatment by chemoimmunotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 2000 |
Management of malignant melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Case-Control Studies; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Life Expectancy; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Risk Factors; Skin; Skin Neoplasms; Sunscreening Agents; Survival Analysis; Time Factors | 2000 |
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Humans; Immunotherapy; Interferons; Melanoma; Odds Ratio; Skin Neoplasms; Time Factors | 2001 |
[Adjuvant therapy of malignant melanoma].
Topics: BCG Vaccine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms | 2001 |
[Treatment of metastasized malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Killer Cells, Lymphokine-Activated; Melanoma; Skin Neoplasms; Survival Rate | 2001 |
Melanoma-associated retinopathy: does autoimmunity prolong survival?
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoimmunity; Dacarbazine; Female; Humans; Immunosuppression Therapy; Interneurons; Lomustine; Melanoma; Membrane Proteins; Paraneoplastic Syndromes; Proteins; Retina; Retinal Diseases; Skin Neoplasms; Survival Rate | 2001 |
Advances in cancer chemotherapy.
Topics: Bleomycin; Burkitt Lymphoma; Carcinoma, Basal Cell; Choriocarcinoma; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Female; Humans; Lomustine; Lung Neoplasms; Methotrexate; Mitosis; Neoplasms; Pregnancy; Skin Neoplasms; Vincristine | 1975 |
The role of immunotherapy in the management of patients with malignant melanoma.
Topics: Bacterial Vaccines; BCG Vaccine; Corynebacterium; Dacarbazine; Dinitrochlorobenzene; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 1979 |
Chemotherapy of malignant melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Skin Neoplasms | 1979 |
Combined modality therapy of malignant melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Skin Neoplasms | 1979 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
Therapy for cutaneous melanoma: an update.
Topics: Adult; Biopsy; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lymph Node Excision; Melanoma; Neoplasm Staging; Pregnancy; Prognosis; Skin Neoplasms | 1990 |
[Diagnosis and prognosis of malignant melanoma].
Topics: Alkaline Phosphatase; Dacarbazine; Female; Humans; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Palpation; Prognosis; Radionuclide Imaging; Skin; Skin Neoplasms | 1985 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferons; Interleukin-2; Lomustine; Melanoma; Prognosis; Skin Neoplasms; Tamoxifen | 1988 |
[An autopsy case of neurocutaneous melanosis associated with intracerebral malignant melanoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Male; Melanoma; Nevus, Pigmented; Nimustine; Nitrosourea Compounds; Skin Neoplasms; Vincristine | 1987 |
Systemic therapy of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Humans; Immunotherapy; Melanoma; Neoplasm Staging; Skin Neoplasms | 1986 |
181 trial(s) available for dacarbazine and Skin Neoplasms
| Article | Year |
|---|---|
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Fusion Proteins; Skin Neoplasms; Survival Analysis; Young Adult | 2019 |
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Male; Melanoma; Middle Aged; Oximes; Patient Selection; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Young Adult | 2020 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2017 |
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme Inhibitors; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib; Young Adult | 2017 |
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Skin Ulcer; Survival Rate; Vinblastine | 2017 |
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Topics: Age Factors; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Health Expenditures; Health Resources; Humans; Imidazoles; Ipilimumab; Kaplan-Meier Estimate; Male; Markov Chains; Melanoma; Middle Aged; Models, Economic; Nivolumab; Oximes; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sex Factors; Skin Neoplasms; Vemurafenib | 2018 |
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Nivolumab; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2019 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brazil; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; Europe; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Melanoma; Middle Aged; Mutation; Neoplasms, Unknown Primary; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; United States | 2013 |
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Young Adult | 2014 |
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Ramucirumab; Skin Neoplasms; Survival Analysis; Young Adult | 2014 |
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Conjunctivitis; Dacarbazine; Dry Eye Syndromes; Eye Diseases; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Uveitis; Vemurafenib; Young Adult | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin Neoplasms; Temozolomide; Tissue Distribution; Tumor Suppressor Proteins | 2015 |
Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Hepatectomy; Humans; Immunotherapy; Interferons; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate | 2014 |
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Drug Monitoring; Female; Humans; Infusions, Intravenous; Intention to Treat Analysis; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin; Skin Neoplasms; Survival Analysis; Tumor Burden | 2015 |
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult | 2015 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Taxoids; Temozolomide | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult | 2016 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Complex; CD4 Antigens; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lipopolysaccharide Receptors; Lymphocyte Count; Lymphocytes; Male; Melanoma; Middle Aged; Monocytes; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome | 2017 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide | 2008 |
Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up.
Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Dacarbazine; Dietary Supplements; Drug Therapy, Combination; Female; Fermentation; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Pilot Projects; Plant Extracts; Skin Neoplasms; Treatment Outcome; Triticum | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Pulmonary Embolism; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2009 |
Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Nerve Growth Factors; Prospective Studies; Recombinant Proteins; Recurrence; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Vindesine | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Purines; Skin Neoplasms; Temozolomide; Thrombocytopenia | 2009 |
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Melanoma; Prognosis; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome | 2009 |
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Thalidomide | 2009 |
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oligodeoxyribonucleotides; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Survival Analysis; Vinblastine; Young Adult | 2009 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide; Thalidomide | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2010 |
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaVbeta3; Male; Melanoma; Middle Aged; Skin Neoplasms | 2010 |
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bosentan; Dacarbazine; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides | 2010 |
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Hexanones; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 2010 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide | 2011 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2012 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Safety; Skin Neoplasms; Temozolomide; Time Factors | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2011 |
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaV; Male; Melanoma; Middle Aged; Skin Neoplasms; Uveitis | 2011 |
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behavior; Cooperative Behavior; Cyclophosphamide; Dacarbazine; Dermatology; Disease Progression; Female; Humans; Interdisciplinary Communication; Male; Medical Oncology; Melanoma; Middle Aged; Palliative Care; Patient Preference; Skin Neoplasms; Societies, Medical; Vincristine | 2011 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Everolimus; Female; Humans; Induction Chemotherapy; Male; Melanoma; Middle Aged; Sirolimus; Skin Neoplasms; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
[Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate | 2002 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Recombinant Proteins; Skin Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2003 |
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine | 2003 |
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival; Temozolomide; Thalidomide | 2003 |
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Quality of Life; Recombinant Proteins; Skin Neoplasms | 2003 |
On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; CD4 Lymphocyte Count; Cisplatin; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Treatment Outcome | 2003 |
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Extracellular Space; Female; Humans; Hyperthermia, Induced; Laser Coagulation; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dacarbazine; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Thrombocytopenia | 2003 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; Dacarbazine; Emotions; Female; Health Status; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Quality of Life; Skin Neoplasms; Sleep; Survival Analysis; Temozolomide | 2003 |
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis | 2004 |
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Onco
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; United States | 2004 |
[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glycosides; Humans; Immunologic Factors; Interferon-alpha; Male; Melanoma; Methylnitrosourea; Middle Aged; Skin Neoplasms; Treatment Outcome | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 2004 |
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclosporine; Dacarbazine; Female; Humans; Immunosuppressive Agents; Interferon-alpha; Interleukin-2; Male; Melanoma; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2005 |
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Nausea; Neutropenia; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Thrombocytopenia; Vinblastine; Vomiting | 2005 |
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon Type I; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Eye Neoplasms; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Melanoma; Middle Aged; Neoplasm Metastasis; Reproducibility of Results; Skin Neoplasms; Survival Analysis; Temozolomide | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Stereotaxic Techniques; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
Topics: Aged; Dacarbazine; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Temozolomide | 2005 |
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Proportional Hazards Models; Recombinant Proteins; Reference Values; Skin Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Tamoxifen; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine | 2005 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neoplasms; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Mouth Neoplasms; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2006 |
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate | 2006 |
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Vinblastine | 2006 |
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Dacarbazine; Female; Humans; Immunologic Factors; Interleukin-10; Interleukin-12; Interleukin-2; Interleukin-6; Interleukin-8; Male; Melanoma; Middle Aged; Receptors, Interleukin-6; Skin Neoplasms; Survival Analysis; Survival Rate; Vinblastine | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrazoles; Skin Neoplasms; Sulfonamides; Survival Analysis; Temozolomide | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Failure; Venous Thrombosis; Withholding Treatment | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Researc
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Patient Compliance; Recombinant Proteins; Skin Neoplasms | 2006 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Purines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2007 |
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Treatment Outcome; Vinblastine | 2007 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Survival Analysis | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Humans; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Odds Ratio; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Skin Neoplasms; Temozolomide | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide | 2008 |
Immunotherapy of malignant melanoma.
Topics: Antigens, Neoplasm; BCG Vaccine; Cholera Vaccines; Clinical Trials as Topic; Dacarbazine; Dinitrochlorobenzene; Double-Blind Method; Humans; Immunotherapy; Interferons; Levamisole; Melanoma; Random Allocation; Skin Neoplasms; Skin Tests; Transfer Factor | 1982 |
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Mouth Diseases; Neutropenia; Random Allocation; Sepsis; Skin Neoplasms; Thrombocytopenia; Vinblastine | 1984 |
Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Topics: Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Random Allocation; Skin Neoplasms | 1983 |
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Humans; Hydroxyurea; Levamisole; Melanoma; Random Allocation; Skin Neoplasms | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sex Factors; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Vincristine | 1984 |
Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Propionibacterium acnes; Prospective Studies; Random Allocation; Skin Neoplasms | 1984 |
Predictability of response to clinical thermochemotherapy by the clonogenic assay.
Topics: Cells, Cultured; Colony-Forming Units Assay; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Hot Temperature; Humans; Liver Neoplasms; Melanoma; Skin Neoplasms; Tumor Stem Cell Assay | 1983 |
A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Topics: Bacterial Vaccines; Clinical Trials as Topic; Dacarbazine; Female; Humans; Immunotherapy; Injections, Intramuscular; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Pancytopenia; Prognosis; Propionibacterium acnes; Skin Neoplasms; Vomiting | 1980 |
[Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methylnitrosourea; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Skin Neoplasms; Time Factors; Vincristine | 1981 |
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prospective Studies; Random Allocation; Skin Neoplasms | 1981 |
A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Piperazines; Random Allocation; Skin Neoplasms | 1982 |
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Prospective Studies; Random Allocation; Semustine; Skin Neoplasms | 1982 |
Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Topics: Adult; Age Factors; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukocyte Count; Melanoma; Middle Aged; Prognosis; Random Allocation; Skin Neoplasms; Skin Tests | 1982 |
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Topics: BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Postoperative Care; Prognosis; Prospective Studies; Random Allocation; Skin Neoplasms | 1982 |
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1995 |
Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vincristine | 1994 |
Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferons; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Treatment Outcome | 1995 |
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Topics: Cisplatin; Combined Modality Therapy; Dacarbazine; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Pilot Projects; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 1995 |
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intravenous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1995 |
Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
Topics: Adult; Aged; CD4 Antigens; CD8 Antigens; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Thymalfasin; Thymosin | 1994 |
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Regression Analysis; Remission Induction; Skin Neoplasms; Survival Analysis; Treatment Outcome | 1995 |
[Prevention and treatment of regional lymphatic metastasis of cutaneous melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Humans; Injections, Intralymphatic; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Methotrexate; Neoplasm Staging; Preoperative Care; Prospidium; Skin Neoplasms; Survival Rate | 1993 |
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Treatment Outcome | 1994 |
Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chi-Square Distribution; Dacarbazine; Drug Synergism; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Survival Analysis | 1993 |
The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Hutchinson's Melanotic Freckle; Interferon-beta; Melanoma; Nimustine; Skin Neoplasms; Survival Rate; Vincristine | 1995 |
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1996 |
[Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].
Topics: Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Staging; Prospective Studies; Recombinant Proteins; Skin Neoplasms | 1996 |
DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms | 1996 |
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 1996 |
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Singapore; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1997 |
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vincristine | 1997 |
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms | 1997 |
Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms | 1997 |
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen | 1998 |
[Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy].
Topics: Administration, Inhalation; Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-12; Lung Neoplasms; Male; Melanoma; Middle Aged; Skin Neoplasms | 1997 |
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Damage; Glutathione Transferase; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Leukocytes, Mononuclear; Melanoma; Neoplasm Staging; Polymerase Chain Reaction; Recombinant Proteins; Skin Neoplasms; Vinblastine | 1998 |
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Neopterin; Nitric Oxide; Skin Neoplasms; Vinblastine | 1998 |
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen | 1998 |
Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Chemotherapy, Adjuvant; Dacarbazine; Female; Flow Cytometry; Humans; Injections, Intralesional; Injections, Intravenous; Interferon-beta; Killer Cells, Natural; Leukocyte Count; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Statistics, Nonparametric; T-Lymphocytes; Treatment Outcome; Vincristine | 1998 |
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Nausea; Prospective Studies; Regression Analysis; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vindesine; Vomiting | 1998 |
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Melanoma, Amelanotic; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Time Factors; Treatment Outcome; Vinblastine | 1998 |
Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Skin Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 1998 |
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms; Tamoxifen | 1999 |
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Eating; Female; Glioma; Humans; Male; Melanoma; Middle Aged; Neoplasms; Skin Neoplasms; Temozolomide; Treatment Outcome | 1999 |
Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm, Residual; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 1999 |
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Female; Health Care Costs; Humans; Infusions, Intravenous; Male; Melanoma; Quality-Adjusted Life Years; Skin Neoplasms; Temozolomide | 2000 |
Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Skin Neoplasms | 2000 |
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA, Antisense; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fever; Follow-Up Studies; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Skin; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Tamoxifen | 2000 |
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Humans; Immunotherapy; Interferons; Melanoma; Odds Ratio; Skin Neoplasms; Time Factors | 2001 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Skin Neoplasms; Survival Rate | 2001 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Procarbazine; Skin Neoplasms; Time Factors; Treatment Outcome; Vincristine | 2002 |
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Epirubicin; Female; Hemodynamics; Humans; Hypoxia; Leg; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Skin Neoplasms; Treatment Outcome | 2002 |
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2002 |
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Male; Melanoma; Middle Aged; Outpatients; Proportional Hazards Models; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2002 |
A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2002 |
Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Salvage Therapy; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Vinblastine | 2001 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Treatment Outcome | 2002 |
[Use of local magnitothermia in the treatment of patients with primary-confined skin melanoma].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Electromagnetic Fields; Female; Hot Temperature; Humans; Injections; Interferon Type I; Interferon-alpha; Lymphatic System; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate | 2002 |
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2002 |
[Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
Topics: Clinical Trials as Topic; Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Drug Evaluation; Humans; Melanoma; Skin Neoplasms; Triazenes | 1978 |
Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Risk; Skin Neoplasms; Triazenes | 1978 |
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Sex Factors; Skin Neoplasms; Triazenes | 1976 |
Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Male; Melanoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes | 1976 |
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1992 |
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Triazenes | 1992 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
[Results of a randomized polychemotherapy study in malignant melanoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Humans; Lomustine; Lymphatic Metastasis; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Skin Neoplasms; Vincristine | 1990 |
The skin: an immunoreactive target organ during interleukin-2 administration?
Topics: Biopsy; Combined Modality Therapy; Cytokines; Dacarbazine; Dermatitis; Humans; Immunohistochemistry; Immunoradiometric Assay; Interferon-gamma; Interleukin-2; Melanoma; Skin Neoplasms; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 1991 |
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 1991 |
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Rate | 1991 |
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Tamoxifen | 1991 |
Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate | 1990 |
[Results of the treatment of advances melanoma of the skin with high daily doses of dacarbazine].
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Time Factors | 1988 |
Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dactinomycin; Female; Humans; Male; Melanoma; Middle Aged; Postoperative Period; Propionibacterium acnes; Prospective Studies; Random Allocation; Skin Neoplasms | 1986 |
[Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Humans; Lomustine; Melanoma; Methylnitrosourea; Prognosis; Skin Neoplasms; Vincristine | 1986 |
Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Procarbazine; Prospective Studies; Random Allocation; Skin Neoplasms; Vindesine | 1986 |
A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Topics: Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Random Allocation; Skin Neoplasms | 1985 |
Adjuvant chemotherapy of malignant melanoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Pilot Projects; Random Allocation; Skin Neoplasms; Vincristine | 1985 |
368 other study(ies) available for dacarbazine and Skin Neoplasms
| Article | Year |
|---|---|
Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Malondialdehyde; Melanoma, Experimental; Metformin; Mice; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Skin Neoplasms; Tumor Suppressor Protein p53 | 2022 |
Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment.
Topics: Animals; Dacarbazine; Humans; Melanoma; Mice; Neoadjuvant Therapy; Salmonella typhimurium; Skin Neoplasms; Tumor Microenvironment | 2022 |
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment | 2022 |
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Neoplasms, Second Primary; Retrospective Studies; Skin Neoplasms; Tumor Microenvironment | 2022 |
Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells.
Topics: Apoptosis; Dacarbazine; DNA; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms | 2023 |
B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms | 2023 |
A step forward on the in vitro and in vivo assessment of a novel nanomedicine against melanoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Mice; Nanomedicine; Skin Neoplasms | 2023 |
MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Fragmentation; Glutathione; Humans; Melanoma; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Skin Neoplasms | 2020 |
Advanced malignant melanoma successfully treated with dacarbazine following anti-PD-1/CTLA-4 treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Female; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 2020 |
Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma.
Topics: Apoptosis; Dacarbazine; Humans; Melanoma; Nivolumab; Skin Neoplasms | 2020 |
In Vitro Anticancer Effects of All-trans Retinoic Acid in Combination with Dacarbazine against CD117+ Melanoma Cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; G1 Phase; Humans; Melanoma; Melanoma, Cutaneous Malignant; Proto-Oncogene Proteins c-kit; Resting Phase, Cell Cycle; Skin Neoplasms; Tretinoin | 2020 |
BRAF L597K mutation: an opportunity to treat.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Back; Dacarbazine; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Vemurafenib | 2021 |
Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Carriers; Drug Compounding; Endothelial Cells; Humans; Isoindoles; Male; Melanoma; Mice; Nanoparticles; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyvinyl Alcohol; Skin Neoplasms; Tissue Distribution; Zinc Compounds | 2021 |
CD47-mediated DTIC-loaded chitosan oligosaccharide-grafted nGO for synergistic chemo-photothermal therapy against malignant melanoma.
Topics: CD47 Antigen; Cell Line, Tumor; Chitosan; Dacarbazine; Doxorubicin; Humans; Melanoma; Nanoparticles; Oligosaccharides; Phototherapy; Photothermal Therapy; Skin Neoplasms | 2021 |
Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Dacarbazine; Dipeptides; Humans; Indoles; Melanoma; Mutation; Skin Neoplasms | 2017 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Early Growth Response Protein 1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lentivirus; Melanoma; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Signal Transduction; Sirolimus; Skin; Skin Neoplasms; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Vemurafenib | 2017 |
TCTP as a therapeutic target in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Female; Gene Expression; Gene Silencing; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; RNA, Messenger; RNA, Small Interfering; Sertraline; Skin Neoplasms; Transfection; Tumor Protein, Translationally-Controlled 1; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2017 |
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; B7-H1 Antigen; Dacarbazine; Female; Japan; Lectins, C-Type; Leukocytes, Mononuclear; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Monocytes; Nimustine; Receptors, Cell Surface; RNA, Messenger; Skin Neoplasms; Vincristine | 2018 |
Inflammatory Cytokine Pattern Is Sex-Dependent in Mouse Cutaneous Melanoma Experimental Model.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogenesis; Cytokines; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Humans; Inflammation Mediators; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Sex; Skin Neoplasms | 2017 |
Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; HeLa Cells; Humans; Interleukin-1alpha; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ribosomal Protein S6 Kinases, 90-kDa; Secretory Pathway; Signal Transduction; Skin Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Dacarbazine; Female; Fibroblast Growth Factor 2; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; Liposomes; Male; Melanoma; Models, Theoretical; Nanoparticles; Neovascularization, Pathologic; Skin Neoplasms; Survivin; Vascular Endothelial Growth Factor A | 2018 |
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Clinical Trials, Phase II as Topic; CTLA-4 Antigen; Dacarbazine; Drug Synergism; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Thymalfasin; Time Factors; Young Adult | 2018 |
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Piperidines; Prognosis; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vemurafenib | 2018 |
Antiproliferative and apoptotic effects of caffeic acid on SK-Mel-28 human melanoma cancer cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Caffeic Acids; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Female; Healthy Volunteers; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms | 2019 |
Bixin, an apocarotenoid isolated from Bixa orellana L., sensitizes human melanoma cells to dacarbazine-induced apoptosis through ROS-mediated cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Bixaceae; Carotenoids; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; G2 Phase Cell Cycle Checkpoints; Humans; Melanoma; Oxidative Stress; Plant Extracts; Reactive Oxygen Species; Seeds; Skin Neoplasms; Vemurafenib | 2019 |
Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Fluvastatin; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Melanoma, Experimental; Mice, Inbred C57BL; Signal Transduction; Simvastatin; Skin Neoplasms; Tumor Burden | 2019 |
Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Melanoma; Reactive Oxygen Species; Skin Neoplasms; Vitamin D | 2019 |
Case of follicular lymphoma presenting with nodules and plaques on the face.
Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Chemoradiotherapy; Dacarbazine; Diagnosis, Differential; Doxorubicin; Glucocorticoids; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Skin; Skin Neoplasms; Treatment Outcome; Vinblastine | 2019 |
Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brazil; Budgets; Dacarbazine; Female; Humans; Male; Melanoma; Molecular Targeted Therapy; National Health Programs; Skin Neoplasms | 2019 |
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms | 2013 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Radiosurgery; Radiotherapy; Retrospective Studies; Skin Neoplasms; Temozolomide; Young Adult | 2014 |
Parthenolide enhances dacarbazine activity against melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interleukin-8; Melanoma; NF-kappa B; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sesquiterpenes; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Has targeted therapy for melanoma made chemotherapy obsolete?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Mutation; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2013 |
Selumetinib increases the efficacy of first-line dacarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2013 |
Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Humans; Lithostathine; Lymphatic Metastasis; Male; Melanoma; Prognosis; Promoter Regions, Genetic; Skin Neoplasms | 2013 |
The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Staging; Neoplasm Transplantation; Neoplastic Stem Cells; Nuclear Proteins; Repressor Proteins; Side-Population Cells; Skin Neoplasms; Tumor Burden | 2013 |
Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Male; Melanoma; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms | 2014 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Immunosuppressive Agents; Ipilimumab; Kidney Transplantation; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mycophenolic Acid; Platinum Compounds; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Skin Neoplasms; Tacrolimus; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Survival Rate; Temozolomide | 2014 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Platinum Compounds; Practice Patterns, Physicians'; Retrospective Studies; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeability; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Melanoma; Melphalan; Neoplasm Transplantation; Oligopeptides; Peptides, Cyclic; Phosphatidylinositol 3-Kinases; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide | 2015 |
[Late gastric metastasis from cutaneous melanoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leg; Lung Neoplasms; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Stomach Neoplasms; Time Factors | 2014 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; Female; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Myo-Inositol-1-Phosphate Synthase; Neoplasm Proteins; Prospective Studies; Proteomics; S100 Proteins; Skin Neoplasms; Tandem Mass Spectrometry; Temozolomide; Young Adult | 2014 |
[Metastatic malignant melanoma of the oesophagus: case report].
Topics: Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Female; Humans; Melanoma; Middle Aged; Neoplasm Staging; Polyps; Skin Neoplasms; Treatment Outcome | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzyme Inhibitors; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide | 2014 |
Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Flow Cytometry; Gene Expression; Humans; Killer Cells, Natural; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; T-Lymphocytes, Regulatory; Transcription Factors; Treatment Outcome | 2014 |
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Proliferation; Dacarbazine; Female; Humans; Incidence; Indoles; Ipilimumab; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib | 2014 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide | 2015 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose F18; Humans; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Myelitis; Paraplegia; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2014 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cannabidiol; Cannabinoids; Cannabinol; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dronabinol; Drug Combinations; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Plant Extracts; Proto-Oncogene Proteins B-raf; ras Proteins; Skin Neoplasms; Temozolomide | 2015 |
Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Dacarbazine; Disease Progression; Drug Therapy, Combination; Male; Melanoma; Mice; Skin Neoplasms | 2015 |
Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Nodal Protein; Skin Neoplasms | 2015 |
Long term survival with the combination of interferon and chemotherapy in metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Ipilimumab; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib | 2015 |
Untreated Hodgkin Lymphoma With Skin Infiltration and Satellite Skin Nodule in a 15-Year-Old Female Adolescent.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Hodgkin Disease; Humans; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed; Vinblastine | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib | 2015 |
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Topics: Adrenal Insufficiency; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Hormone Replacement Therapy; Humans; Hypopituitarism; Hypothyroidism; Interferon-alpha; Interleukin-2; Ipilimumab; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Parietal Lobe; Radiosurgery; Sentinel Lymph Node Biopsy; Shoulder; Skin Neoplasms; Treatment Outcome; Vinblastine | 2015 |
Complete Remission in Systemic Skin Interdigitating Dendritic Cell Sarcoma after ABVD Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Dacarbazine; Dendritic Cell Sarcoma, Interdigitating; Doxorubicin; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Immunophenotyping; Male; Middle Aged; Positron-Emission Tomography; Remission Induction; Skin; Skin Neoplasms; Vinblastine | 2015 |
Temozolomide for central nervous system involvement in mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Dacarbazine; Dexamethasone; Female; Humans; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Retreatment; Skin Neoplasms; Temozolomide; Treatment Outcome | 2016 |
Is chemotherapy still an option in the treatment of melanoma?
Topics: Albumins; Dacarbazine; Female; Humans; Male; Melanoma; Paclitaxel; Skin Neoplasms | 2015 |
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamydophila pneumoniae; Dacarbazine; Humans; Lomustine; Lung Neoplasms; Macrophage Activation; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Sepsis; Skin Neoplasms; Treatment Outcome; Vincristine | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histones; Humans; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2016 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinases; Phosphorylation; Skin Neoplasms; Temozolomide | 2016 |
DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.
Topics: Alanine Transaminase; Animals; Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Creatinine; Dacarbazine; Drug Delivery Systems; Humans; Immunotherapy; Leukocytes; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms | 2016 |
In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease Models, Animal; Female; Humans; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Skin Neoplasms | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Hedyotis; Humans; Lobelia; Melanoma; Phytotherapy; Plant Extracts; Plants, Medicinal; Reactive Oxygen Species; Scutellaria; Skin Neoplasms; Solanum nigrum; Solvents; Tandem Mass Spectrometry; Temozolomide; Water | 2016 |
A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Topics: Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Perylene; Photochemotherapy; Skin Neoplasms | 2017 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Chromones; Dacarbazine; Drug Synergism; Humans; Melanoma; Morpholines; Skin Neoplasms; Temozolomide | 2017 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Indoles; Insurance Claim Review; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib; Young Adult | 2017 |
Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; C-Reactive Protein; Colonic Neoplasms; Colonoscopy; Dacarbazine; Endoscopy, Gastrointestinal; Fatal Outcome; Female; Humans; Ileocecal Valve; Intussusception; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Nivolumab; Occult Blood; Skin; Skin Neoplasms; Tomography, X-Ray Computed | 2017 |
[Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Melanoma; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy, Adjuvant; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2008 |
[In vitro drug sensitivity profiling in melanoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Humans; In Vitro Techniques; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Rate; Tumor Stem Cell Assay | 2008 |
Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunologic Factors; Injections, Intravenous; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine | 2008 |
Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Treatment Outcome | 2008 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukins; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Suppressor Protein p53 | 2008 |
Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Melanoma; Pyrazoles; Skin Neoplasms; Sulfonamides; Tongue Neoplasms | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanins; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Organometallic Compounds; Positron-Emission Tomography; Radioimmunotherapy; Skin Neoplasms | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dacarbazine; Drug Therapy, Combination; Early Detection of Cancer; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphatic Metastasis; Male; Melanoma; Neoplasms, Multiple Primary; Skin Neoplasms; Splenic Neoplasms; Temozolomide | 2009 |
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dacarbazine; Female; Humans; Lung Neoplasms; Melanoma; Mice; Mice, SCID; Skin Neoplasms; Vinblastine; Xenograft Model Antitumor Assays | 2009 |
Dacarbazine induced acute myeloid leukemia in melanoma.
Topics: Dacarbazine; Humans; Leukemia, Myeloid, Acute; Male; Melanoma; Skin Neoplasms | 2009 |
Epstein-Barr virus-positive Hodgkin lymphoma-like earlobe lymphoid infiltrate: case report.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Ear Diseases; Epstein-Barr Virus Infections; Female; Hodgkin Disease; Humans; Immunophenotyping; Lymphatic Metastasis; Middle Aged; Skin Neoplasms; Vinblastine | 2009 |
Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Chemokine CXCL11; Chemokine CXCL2; Dacarbazine; Dermatologic Agents; Dimethyl Fumarate; Drug Therapy, Combination; Fumarates; Humans; Lymphatic Metastasis; Lymphatic Vessels; Melanoma; Mice; Mice, SCID; RNA, Messenger; Sentinel Lymph Node Biopsy; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
[Treatment of metastatic malignant melanoma localized to an extremity].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Lower Extremity; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Registries; Remission Induction; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome; Upper Extremity | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide | 2010 |
Congenital pigment synthesizing melanoma of the scalp.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Infant; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Melanins; Melanoma; Skin Neoplasms; Vinblastine | 2010 |
Generalized melanosis and melanuria in a patient with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Diphosphonates; Humans; Imidazoles; Male; Melanins; Melanoma; Melanosis; Middle Aged; Positron-Emission Tomography; Skin Neoplasms; Zoledronic Acid | 2010 |
Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; Humans; Melanoma; Predictive Value of Tests; Skin Neoplasms; Tumor Suppressor Protein p53 | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Analysis; Survivors; Temozolomide; Treatment Outcome; Young Adult | 2010 |
MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Eye Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Skin Neoplasms; Tumor Suppressor Proteins | 2010 |
Amelanotic malignant melanoma where primary lesion was discovered 5 years after metastasis in the lymph node.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Doxorubicin; Foot Diseases; Heel; Humans; Lymphatic Metastasis; Male; Melanoma, Amelanotic; Middle Aged; Neoplasm Staging; Prognosis; Skin Neoplasms; Tomography, Emission-Computed; Vincristine | 2010 |
Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo.
Topics: Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Humans; Interferon-beta; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nimustine; Osteomyelitis; Skin Neoplasms; Vincristine; Vitiligo | 2010 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Humans; In Vitro Techniques; Melanoma; Melphalan; Mice; Mice, Nude; Mice, SCID; Resveratrol; Skin Neoplasms; Stilbenes; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2010 |
Malignant melanoma of the breast: N-isopropyl-p-(123) I-iodoamphetamine single photon emission computed tomography ((123) I-IMP SPECT) is useful for the detection of metastasis.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Interferon-beta; Iofetamine; Liver Neoplasms; Lung Neoplasms; MART-1 Antigen; Mastectomy, Modified Radical; Melanoma; Middle Aged; Neoplasm Staging; Nimustine; Nipples; Radiopharmaceuticals; S100 Proteins; Skin Neoplasms; Tamoxifen; Tomography, Emission-Computed, Single-Photon; Vincristine | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 Phase; Gene Silencing; Humans; Melanoma; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; S Phase; Skin Neoplasms; Temozolomide | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
[Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Death; Cisplatin; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Female; Gene Expression; Humans; Interferon-gamma; Ki-1 Antigen; Lomustine; Lymphocyte Count; Lymphocytes; Male; Melanoma; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Recombinant Proteins; Skin Neoplasms; Treatment Outcome | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; Male; Melanoma; Mutation; Proto-Oncogene Proteins p21(ras); Skin Neoplasms; Temozolomide | 2011 |
Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Disease Progression; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Lymphocytes; Male; Melanoma; Middle Aged; Osteonectin; Skin Neoplasms; Stromal Cells; Tumor Microenvironment; Young Adult | 2011 |
[Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Kaplan-Meier Estimate; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prognosis; Skin Neoplasms; Skin Ulcer | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immunohistochemistry; Injections, Intralesional; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retinal Neoplasms; Risk Assessment; Skin Neoplasms; Temozolomide; Treatment Outcome; Visual Acuity; Visual Fields | 2011 |
Strides in melanoma announced: maximizing value comes next.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Secondary Prevention; Skin Neoplasms; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Verrucous; Combined Modality Therapy; Dacarbazine; Dermatomycoses; Diagnosis, Differential; Ependymoma; Fatal Outcome; Folliculitis; Frontal Lobe; Hand Dermatoses; Humans; Immunocompromised Host; Keratosis; Male; Neutrophils; Pyrimidines; Skin Neoplasms; Staining and Labeling; Temozolomide; Triazoles; Voriconazole | 2011 |
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2011 |
[Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Damage; DNA Repair; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Lomustine; Lymphocytes; Male; Melanoma; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Predictive Value of Tests; Prognosis; Skin Neoplasms; Treatment Outcome | 2011 |
The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Female; Ku Autoantigen; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Rad51 Recombinase; RNA, Small Interfering; Sendai virus; Skin Neoplasms | 2012 |
Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Forearm; Head and Neck Neoplasms; Humans; Hyperpigmentation; Male; Melanoma; Middle Aged; Scalp; Skin Neoplasms; Torso | 2012 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; Mice; Mice, Inbred C57BL; Skin Neoplasms; T-Lymphocytes; Temozolomide | 2011 |
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Flow Cytometry; Humans; Immunotherapy; Melanoma; Microscopy, Confocal; Nanoconjugates; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms | 2011 |
[Linear porokeratosis].
Topics: Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Foot Diseases; Humans; Immunotherapy, Active; Lasers, Gas; Low-Level Light Therapy; Melanoma; Porokeratosis; Skin Neoplasms; Toes | 2011 |
[The usefulness of neo- and adjuvant therapy in the treatment of cutaneous melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome; Vincristine | 2011 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozygosity; MAP Kinase Kinase Kinase 5; MAP Kinase Kinase Kinases; Melanoma; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2011 |
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells.
Topics: Aged; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Foot; Humans; Male; Melanoma; Molecular Targeted Therapy; Neoplastic Stem Cells; Remission Induction; Rituximab; Skin Neoplasms; Tumor Burden | 2012 |
[Sustained remission of blastic plasmacytoid dendritic cell neoplasm with ABVD chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dendritic Cells; Doxorubicin; Humans; Male; Remission Induction; Skin Neoplasms; Treatment Outcome; Vinblastine | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Brain Neoplasms; Calpain; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Selenium; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Membrane; Cell Survival; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Neoplasm, Residual; Skin Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Two cases of malignant melanoma of the toe developed skin ulcers following local injection of natural beta-interferon.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Foot Diseases; Humans; Interferon-beta; Melanoma; Nimustine; Skin Neoplasms; Skin Ulcer; Vincristine | 2012 |
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine; Young Adult | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosis; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Isoenzymes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Response Elements; Retinal Dehydrogenase; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Tretinoin | 2012 |
p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nimustine; Prognosis; Ribonucleotide Reductases; RNA Interference; Skin Neoplasms; Transfection; Vincristine; Young Adult | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplastic Stem Cells; Skin Neoplasms; Temozolomide | 2012 |
Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Humans; Interferon-gamma; Killer Cells, Natural; Ligands; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; NK Cell Lectin-Like Receptor Subfamily K; Skin Neoplasms; Up-Regulation | 2013 |
[A silent-growing and fast-killing melanoma in a teenager].
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Back Pain; Combined Modality Therapy; Cyclin D1; Dacarbazine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gene Amplification; Head and Neck Neoplasms; Humans; Immunotherapy; In Situ Hybridization, Fluorescence; Ipilimumab; Lymphatic Metastasis; Melanoma; Nausea; Neoplasm Proteins; Neoplasms, Second Primary; Nevus; Osteolysis; Scalp; Skin Neoplasms; Weight Loss | 2012 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Glioblastoma; Humans; Kaplan-Meier Estimate; Mibefradil; Mice; Neoplasm Transplantation; Skin Neoplasms; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Indoles; Interleukin-2; Ipilimumab; Melanoma; Neoplasm Staging; Palliative Care; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Radiosurgery; raf Kinases; Skin Neoplasms; Sulfonamides; Vemurafenib | 2013 |
Angiokeratoma corporis diffusum in a patient with Hodgkin lymphoma: a new paraneoplastic skin manifestation?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Fabry Disease; Follow-Up Studies; Hodgkin Disease; Humans; Male; Paraneoplastic Syndromes; Skin Neoplasms; Vinblastine | 2013 |
Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
Topics: Animals; CD8-Positive T-Lymphocytes; Dacarbazine; Humans; Killer Cells, Natural; Melanoma, Experimental; NK Cell Lectin-Like Receptor Subfamily K; Skin Neoplasms | 2013 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Temozolomide; Temporal Lobe | 2002 |
Complete remission of metastatic clear cell sarcoma with DAV chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nimustine; Sarcoma, Clear Cell; Skin Neoplasms; Treatment Outcome; Vincristine | 2003 |
Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Radionuclide Imaging; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Uveal Neoplasms; Verapamil | 2003 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Eye Neoplasms; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lymphocyte Activation; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; T-Lymphocyte Subsets; Temozolomide; Treatment Outcome | 2003 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Melanoma; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Leukemia, Erythroblastic, Acute; Leukocytes, Mononuclear; Lymphocytes; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2003 |
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Skin Neoplasms; Treatment Outcome; Vindesine | 2003 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; Quality of Life; Skin Neoplasms; Temozolomide | 2003 |
Angiomatoid metastatic melanoma.
Topics: Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome | 2004 |
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; DNA, Neoplasm; Female; Humans; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Melanoma; Melanosis; Melanosomes; Microscopy, Electron; Polymerase Chain Reaction; Skin; Skin Neoplasms; Tumor Lysis Syndrome; Vinblastine | 2004 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial Nerves; Dacarbazine; Fatal Outcome; Headache; Humans; Lymph Nodes; Magnetic Resonance Imaging; Male; Melanoma; Neoplasm Metastasis; Ophthalmoplegia; Orbital Neoplasms; Risk Factors; Skin Neoplasms; Survival Rate; Temozolomide | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2004 |
Chemotherapy for melanoma: the resultant of conflicting vectors.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Skin Neoplasms | 2004 |
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Melanoma; Mice; Mice, Nude; Skin Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome | 2004 |
Cutaneous involvement in Hodgkin's lymphoma: report of two cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Diagnosis, Differential; Epirubicin; Female; Hodgkin Disease; Humans; Skin; Skin Neoplasms; Vinblastine | 2004 |
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Extremities; Female; Infusions, Parenteral; Melanoma; Melphalan; Probability; Random Allocation; Rats; Rats, Nude; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Skin Neoplasms; Survival Rate; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2004 |
Breast metastases from cutaneous malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 2004 |
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Survival Rate; T-Lymphocytes, Regulatory; Treatment Outcome; Vinblastine | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Retrospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vinblastine; Vulvar Neoplasms | 2004 |
Serum bcl-2 and survivin levels in melanoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Microtubule-Associated Proteins; Middle Aged; Neoplasm Proteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Skin Neoplasms; Survivin | 2004 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
[Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Topics: Adult; Antigens, CD; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Male; Melanoma; Skin Neoplasms | 2002 |
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Mice; Mice, SCID; Microcirculation; Skin Neoplasms; Thalidomide; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2005 |
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Treatment Outcome; Vincristine | 2005 |
Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Vinblastine | 2005 |
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; MART-1 Antigen; Melanoma; Middle Aged; N-Acetylgalactosaminyltransferases; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Paired Box Transcription Factors; PAX3 Transcription Factor; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2005 |
Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Dacarbazine; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melanoma; Radiotherapy, Adjuvant; Skin Neoplasms | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Interactions; Fluorenes; Glycoside Hydrolases; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Skin Neoplasms; Temozolomide | 2005 |
Benign pleural schwannoma secondary to radiotherapy for Hodgkin disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Basal Cell; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Goiter, Nodular; Hodgkin Disease; Humans; Mechlorethamine; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neurilemmoma; Pleural Neoplasms; Prednisone; Procarbazine; Radiotherapy; Recurrence; Skin Neoplasms; Vinblastine; Vincristine | 2005 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; Cell Proliferation; Dacarbazine; Drug Delivery Systems; Esterases; Esters; Humans; Liver; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Rats; Skin; Skin Neoplasms; Swine; Temozolomide; Tumor Cells, Cultured | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Cross-Sectional Studies; Dacarbazine; Drug Hypersensitivity; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Time Factors | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Humans; Injections, Intra-Arterial; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Rats; Rats, Inbred Strains; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cisplatin; Coronary Artery Disease; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Myocardial Infarction; Nimustine; Skin Neoplasms; Tamoxifen | 2006 |
Adjuvant therapy of cutaneous melanoma -- current status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2006 |
The course of melanoma-associated vitiligo: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Vinblastine; Vitiligo | 2006 |
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2006 |
Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disseminated Intravascular Coagulation; Humans; Liver Neoplasms; Male; Melanoma; Skin Neoplasms; Treatment Outcome; Vinblastine | 2006 |
Hematoma-like metastases.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Dacarbazine; Diagnosis, Differential; Fatal Outcome; Hematoma; Hemorrhage; Humans; Liver Neoplasms; Male; Melanoma; Muscle Neoplasms; Paresis; Skin; Skin Neoplasms; Vascular Neoplasms | 2006 |
Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzamides; Chlorambucil; Dacarbazine; Disease Models, Animal; Humans; Injections, Intraperitoneal; Male; Maximum Tolerated Dose; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Skin Neoplasms; Survival Rate; Tumor Cells, Cultured | 2006 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Repair; Dose-Response Relationship, Drug; Fever; Humans; Inhibitory Concentration 50; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide | 2007 |
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dinitrochlorobenzene; Disease-Free Survival; Female; Germany; Humans; Irritants; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis | 2007 |
Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vindesine | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Infusions, Intravenous; Melanoma; Melphalan; Neoplasm Transplantation; Rats; Rats, Nude; Skin Neoplasms; Temozolomide | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line, Tumor; Cisplatin; Dacarbazine; Disease Models, Animal; Female; Galectin 1; Gene Expression Regulation, Neoplastic; HSP72 Heat-Shock Proteins; Melanoma; Mice; Mice, Knockout; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Mice; Mice, SCID; Oncogene Protein v-akt; Protein Kinases; PTEN Phosphohydrolase; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |
Molecular classification of patients with malignant melanoma for new therapeutic strategies.
Topics: Combined Modality Therapy; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Skin Neoplasms; Thionucleotides | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug Carriers; Drug Delivery Systems; Emulsions; Esters; In Vitro Techniques; Melanoma; Mice; Mice, Hairless; Myristates; Oleic Acid; Permeability; Pharmaceutical Vehicles; Polyethylene Glycols; Prodrugs; Rats; Skin Absorption; Skin Neoplasms; Solubility; Temozolomide; Vitamin E | 2007 |
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infant, Newborn; Liver Neoplasms; Male; Melanoma; Microphthalmos; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Skin Neoplasms; Tamoxifen | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; G2 Phase; Gene Amplification; Genome, Viral; Humans; Melanoma; Oncolytic Virotherapy; Skin Neoplasms; Temozolomide; Treatment Outcome; Tumor Cells, Cultured | 2007 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Guanine; Humans; Luciferases; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2007 |
Genasense: it ain't over till the fat lady sings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Approval; Humans; Melanoma; Oligonucleotides, Antisense; Randomized Controlled Trials as Topic; Skin Neoplasms; Thionucleotides; United States; United States Food and Drug Administration | 2007 |
Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Genetic Vectors; Humans; Melanoma; Membrane Cofactor Protein; Mice; Mice, Nude; Oncolytic Virotherapy; Recoverin; Skin Neoplasms; Viral Fusion Proteins; Viral Proteins; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays | 2008 |
CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; CD56 Antigen; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon Regulatory Factor-1; Interferon-alpha; Killer Cells, Natural; Lectins, C-Type; Male; Melanoma; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Tretinoin | 2007 |
Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lymphatic Metastasis; Melanoma; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Staging; Patient Selection; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk; Skin Neoplasms; Survival Analysis; Treatment Failure | 2008 |
Acquired hypopigmentation (leukoderma) as a presenting feature of metastatic amelanotic melanoma with brain involvement.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Dexamethasone; Humans; Hypopigmentation; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Melanoma, Amelanotic; Middle Aged; Neurologic Examination; Skin Neoplasms; Temozolomide | 2007 |
[Dacarbazine: deticene].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Skin Neoplasms | 2007 |
Langerhans cell sarcoma emanating from the upper arm skin: successful treatment by MAID regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Langerhans Cell Sarcoma; Male; Mesna; Skin Neoplasms | 2008 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2008 |
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vinblastine | 2007 |
Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Topics: Adjuvants, Immunologic; Administration, Topical; Animals; Antineoplastic Agents, Alkylating; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Injections, Intraperitoneal; Melanoma; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2008 |
Leser-Trelat sign in metastasized malignant melanoma.
Topics: Aged, 80 and over; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; Keratosis, Seborrheic; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Palliative Care; Paraneoplastic Syndromes; Risk Assessment; Skin Neoplasms | 2009 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Humans; Lung Neoplasms; Melanoma; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Skin; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Dacarbazine; Female; gamma-Glutamyltransferase; Humans; Melanoma; Prednisone; Skin Neoplasms | 1981 |
Management of malignant melanoma: a retrospective analysis of 182 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms | 1984 |
Modern problems of clinical chemotherapy of malignant tumours.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Methylnitrosourea; Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Vincristine | 1980 |
[The glucagonoma syndrome--a not-so-well-known cutaneous paraneoplastic condition. Case report].
Topics: Adenoma, Islet Cell; Adrenal Cortex Hormones; Dacarbazine; Glucagonoma; Humans; Male; Middle Aged; Pancreatic Neoplasms; Precancerous Conditions; PUVA Therapy; Skin Neoplasms; Syndrome | 1984 |
[Isolated hyperthermic extremity perfusion with vindesine, dacarbazine and cisplatin in the treatment of malignant melanomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Humans; Leg; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Skin Neoplasms; Vinblastine; Vindesine | 1984 |
Adverse photo reaction to decarbazine (DTIC).
Topics: Adult; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Postoperative Complications; Skin Neoplasms | 1981 |
[Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Indomethacin; Lung Neoplasms; Male; Melanoma; Nimustine; Nitrosourea Compounds; Pain, Intractable; Picibanil; Skin Neoplasms; Suppositories; Vincristine | 1984 |
Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
Topics: Adult; Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rosette Formation; Skin Neoplasms; T-Lymphocytes; Thymus Extracts | 1983 |
Tourniquet infusion with DTIC in therapy-resistant melanoma on the extremities: a pilot study.
Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Skin Neoplasms | 1983 |
[Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Topics: BCG Vaccine; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Skin Neoplasms | 1983 |
Regional perfusion with cis-platinum and dacarbazine.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extremities; Follow-Up Studies; Humans; Melanoma; Skin Neoplasms | 1983 |
Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide.
Topics: Arm; Chemotherapy, Cancer, Regional Perfusion; Creatinine; Dacarbazine; Follow-Up Studies; Humans; Leg; Leukocyte Count; Liver Function Tests; Melanoma; Skin Neoplasms | 1984 |
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Child; Dacarbazine; Female; Foot; Hand; Humans; Japan; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Proteoglycans; Skin Neoplasms; Vincristine | 1984 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Middle Aged; Skin Neoplasms | 1984 |
Cell kinetic studies of the effect of DTIC combined with fluorescent light or UVA irradiation on human melanoma cell line (SEKI, II).
Topics: Cell Cycle; Cells, Cultured; Dacarbazine; Fluorescence; Humans; Kinetics; Melanoma; Skin Neoplasms; Ultraviolet Rays | 1982 |
[Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
Topics: Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Female; Humans; Lymphoma; Melanoma; Middle Aged; Skin Neoplasms | 1982 |
Adjuvant dacarbazine in cutaneous melanoma.
Topics: Dacarbazine; Humans; Melanoma; Skin Neoplasms | 1983 |
Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.
Topics: Chemical and Drug Induced Liver Injury; Dacarbazine; Female; Hepatic Veins; Humans; Liver Diseases; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms; Thrombosis | 1983 |
[New modifications in isolated extremity perfusion ].
Topics: Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Hot Temperature; Humans; Leg; Mechlorethamine; Melanoma; Melphalan; Skin Neoplasms | 1982 |
[Malignant melanoma. Clinicopathological analysis of 37 cases (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms | 1982 |
[A case of malignant melanoma responded to chemotherapy including DTIC and local injection of OK-432].
Topics: Adult; Biological Products; Dacarbazine; Drug Therapy, Combination; Female; Humans; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Skin Neoplasms; Vincristine | 1982 |
[A combination chemotherapy of ACNU and DTIC for advanced malignant melanoma].
Topics: Adult; Aged; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Skin Neoplasms | 1982 |
[Cell kinetic studies on human melanoma cell line (SEKI II) under the effect of DTIC with fluorescent light and UVA irradiation (author's transl)].
Topics: Cell Cycle; Cell Line; Dacarbazine; Humans; Light; Melanoma; Neoplasms, Experimental; Photic Stimulation; Skin Neoplasms; Ultraviolet Rays | 1980 |
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Male; Melanoma; Metoclopramide; Middle Aged; Mycobacterium bovis; Skin Neoplasms; Vomiting | 1980 |
Chemoimmunotherapy for disseminated malignant melanoma with DTIC, ACNU, VCR and OK432. Case presentation of two complete and one partial reponse out of fifteen attempts.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Skin Neoplasms; Vincristine | 1982 |
Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Chromatography, Affinity; Dacarbazine; Drug Administration Schedule; Female; Humans; Immunity, Cellular; Immunization; Male; Melanoma; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Random Allocation; Recurrence; Skin Neoplasms | 1982 |
[Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Skin Neoplasms | 1982 |
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Liver; Male; Melanoma; Middle Aged; Skin Neoplasms | 1982 |
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leucine; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Proteoglycans; Skin Neoplasms; Vincristine | 1982 |
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
Topics: Aged; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Hepatic Veins; Humans; Liver; Lymphatic Metastasis; Male; Melanoma; Skin Neoplasms | 1981 |
[Scintigraphy of liver after combined chemo-/immunotherapy with malignant melanoma (author's transl)].
Topics: Adult; BCG Vaccine; Dacarbazine; Female; Humans; Liver; Male; Melanoma; Middle Aged; Radionuclide Imaging; Skin Neoplasms | 1981 |
Dacarbazine-induced photosensitivity reaction.
Topics: Aged; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Photosensitivity Disorders; Skin; Skin Neoplasms | 1981 |
[Effect of DTIC on the level of various blood components in melanoma].
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Proteins; Dacarbazine; Female; Hematocrit; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms | 1981 |
Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 1981 |
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neoplasms; Vitreous Body | 1981 |
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Procarbazine; Ricin; Skin Neoplasms; Time Factors; Transplantation, Heterologous; Vinblastine | 1980 |
[Phototoxic dermatitis caused by DTIC-treatment].
Topics: Dacarbazine; Humans; Melanoma; Photosensitivity Disorders; Skin Neoplasms | 1980 |
[Photosensitization with DTIC therapy in metastatic malignant melanoma].
Topics: Aged; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Photosensitivity Disorders; Skin Neoplasms | 1980 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1994 |
Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferons; Lomustine; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 1995 |
Statistical survey from 1982 to 1991 of 49 patients with malignant melanocytic tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Dacarbazine; Female; Humans; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Prognosis; Skin Neoplasms; Survival Rate; Vincristine | 1995 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Nimustine; Peplomycin; Skin Neoplasms; Vincristine | 1993 |
Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Skin Neoplasms; Survival Analysis; Vinblastine | 1994 |
[Melanoma metastasis in the oropharynx].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nasopharyngeal Neoplasms; Nasopharynx; Skin Neoplasms | 1994 |
Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Dacarbazine; Dactinomycin; Evaluation Studies as Topic; Extremities; Humans; Hyperthermia, Induced; Incidence; Melanoma; Melphalan; Neoplasm Metastasis; Osteosarcoma; Rhabdomyolysis; Skin Neoplasms; Treatment Outcome | 1993 |
Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Dacarbazine; Humans; Immunoenzyme Techniques; Immunohistochemistry; Intercellular Adhesion Molecule-1; Interferon-beta; Liver Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Vincristine | 1993 |
Malignant histiocytosis with multiple skin lesions in a dog.
Topics: Animals; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dog Diseases; Dogs; Heart Neoplasms; Histiocytic Sarcoma; Male; Mitoxantrone; Muscles; Myocardium; Prednisolone; Skin; Skin Neoplasms; Vincristine | 1993 |
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1993 |
[Dramatic remission of a multiple metastasized melanoma caused by chemo-immunotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Liver Neoplasms; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Splenic Neoplasms | 1993 |
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1995 |
[A case of adrenal gland metastasis of a cutaneous melanoma treated by excision with 3-year survival].
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Follow-Up Studies; Humans; Male; Melanoma; Skin Neoplasms; Vindesine | 1996 |
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Division; Cell Nucleus; Dacarbazine; Female; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Melanoma; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms | 1997 |
Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Survival Rate; Thiotepa | 1997 |
Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cysteinyldopa; Dacarbazine; Disease Progression; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms | 1997 |
Paralytic ileus associated with a combination of dacarbazine-nimustine hydrochloride-vincristine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Intestinal Pseudo-Obstruction; Melanoma; Nimustine; Skin Neoplasms; Vincristine | 1997 |
Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Soft Tissue Neoplasms; Survival Rate; Time Factors | 1997 |
[Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Female; Follow-Up Studies; Humans; Immunotherapy; Infusions, Intravenous; Irritants; Male; Melanoma; Middle Aged; Skin; Skin Neoplasms; Treatment Outcome | 1998 |
Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Dacarbazine; Edema; Extremities; Female; Humans; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Perfusion; Recurrence; Skin Neoplasms | 1998 |
Malignant blue nevus of the scalp.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Humans; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Nevus, Blue; Scalp; Skin Neoplasms; Vindesine | 1998 |
[The role of glutathione and glutathione-S-transferase in neoplasm drug resistance].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Erythrocytes; Etoposide; Female; Glutathione; Glutathione Transferase; Humans; Male; Melanoma; Ovarian Neoplasms; Propionates; Skin Neoplasms; Testicular Neoplasms | 1998 |
[At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Tumor Cells, Cultured | 1998 |
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1998 |
[Chemotherapy of malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interleukins; Lomustine; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Tamoxifen; Vincristine | 1998 |
Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Skin Diseases; Skin Neoplasms; Tamoxifen; Vinblastine | 1999 |
SODs are involved in the regulation of ICAM-1 expression in human melanoma and endothelial cells.
Topics: Cells, Cultured; Cytoplasm; Dacarbazine; Endothelium, Vascular; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Intercellular Adhesion Molecule-1; Isoenzymes; Melanoma; Metalloporphyrins; Mitochondria; Neoplasm Proteins; Oxidative Stress; Paraquat; Skin Neoplasms; Superoxide Dismutase; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Umbilical Veins | 1999 |
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Topics: Adenine; Adult; Aged; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; Female; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Predictive Value of Tests; Sensitivity and Specificity; Skin Neoplasms | 2000 |
Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms; Vincristine | 2000 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quality of Life; Skin Neoplasms; Survival Analysis; Temozolomide | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Dacarbazine; Drug Synergism; Humans; Immunologic Factors; Interferons; Interleukin-2; Melanoma; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Research Design; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vinblastine | 2000 |
Cutaneous malignant melanoma in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Male; Melanoma; Neoplasm Staging; Prognosis; Risk Factors; Skin Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Vindesine | 2000 |
Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate; Time Factors | 2000 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms; Temozolomide | 2000 |
Necrosis in melanoma metastases with treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2001 |
Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Antigens, CD; Antigens, Differentiation; Antineoplastic Agents, Alkylating; CD4-CD8 Ratio; Dacarbazine; Drug Administration Schedule; Female; Flow Cytometry; Humans; Immunologic Factors; Interferon-alpha; Killer Cells, Natural; Male; Melanoma; Membrane Glycoproteins; Middle Aged; NAD+ Nucleosidase; Skin Neoplasms; Treatment Outcome | 2001 |
Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.
Topics: Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressure Liquid; Dacarbazine; Extracellular Space; Female; Humans; Male; Melanoma; Microdialysis; Middle Aged; Skin Neoplasms | 2001 |
Radiation recall dermatitis in a patient treated with dacarbazine.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glucocorticoids; Humans; Melanoma; Prednisolone; Radiodermatitis; Recurrence; Skin Neoplasms | 2001 |
Is there a standard for the palliative treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Evidence-Based Medicine; Humans; Interferons; Interleukin-2; Melanoma; Palliative Care; Randomized Controlled Trials as Topic; Skin Neoplasms; Treatment Outcome | 2002 |
Biochemotherapy for advanced melanoma: maybe it is real.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Interleukin-2; Melanoma; Skin Neoplasms; Vincristine | 2002 |
Chemotherapy for advanced Kaposi sarcoma.
Topics: Aged; Bleomycin; Dacarbazine; Dactinomycin; Doxorubicin; Humans; Male; Mechlorethamine; Middle Aged; Procarbazine; Sarcoma, Kaposi; Skin Neoplasms; Vinblastine; Vincristine | 1975 |
Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Topics: Adult; Aged; Ancitabine; Brain Neoplasms; Cytarabine; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Middle Aged; Neoplasm Metastasis; Retroperitoneal Neoplasms; Skin Neoplasms; Triazenes | 1976 |
[Dacarbazin -- therapy of metastazising malignant melanoma (author's transl)].
Topics: Adult; Dacarbazine; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms | 1979 |
Dacarbazine and melphalan. Enhancement by dosage scheduling of the effect in combination treatment on the Harding-Passey melanoma in C3D2F1 mice.
Topics: Animals; Dacarbazine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Melanoma; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasms, Experimental; Skin Neoplasms; Triazenes | 1979 |
Feasibility of integration of modalities in melanomas and sarcomas.
Topics: BCG Vaccine; Dacarbazine; Estramustine; Humans; Melanoma; Melphalan; Radiotherapy Dosage; Sarcoma; Skin Neoplasms | 1979 |
[Treatment of advanced malignant melanoma with DTIC].
Topics: Adult; Aged; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes | 1979 |
A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Procarbazine; Skin Neoplasms; Vinblastine | 1979 |
Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Hematopoiesis; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Monocytes; Skin Neoplasms | 1979 |
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Topics: Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Drug Hypersensitivity; Eosinophils; Female; Humans; Liver Diseases; Melanoma; Middle Aged; Skin Neoplasms | 1979 |
[Chemotherapy of malignant melanoma using DTIC].
Topics: Adult; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes | 1977 |
Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
Topics: Adult; Aged; Aminoimidazole Carboxamide; BCG Vaccine; Dacarbazine; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Postoperative Care; Risk; Skin Neoplasms; Triazenes | 1978 |
Clinical pharmacology of systemic chemotherapeutic agents in skin neoplasms.
Topics: Antineoplastic Agents; Dacarbazine; Dactinomycin; Humans; Kinetics; Methotrexate; Nitrosourea Compounds; Skin Neoplasms | 1978 |
[Combined immuno-chemotherapy of malignant melanoma: epidemiological elements].
Topics: Adolescent; Adult; Aged; Dacarbazine; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Remission, Spontaneous; Skin Neoplasms | 1978 |
Chemotherapy of unresectable or recurrent metastatic malignant melanomas: an update.
Topics: Amphotericin B; BCG Vaccine; Dacarbazine; Drug Combinations; Estradiol Congeners; Female; Hot Temperature; Humans; Melanoma; Methotrexate; Neoplasm Metastasis; Nitrosourea Compounds; Skin Neoplasms | 1979 |
[Melanoma therapy].
Topics: BCG Vaccine; Dacarbazine; Humans; Immunotherapy; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Mycobacterium bovis; Skin Neoplasms | 1976 |
Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins: preliminary results in patients with disseminated disease.
Topics: Adolescent; Adult; Aged; Antibodies, Neoplasm; Chlorambucil; Dacarbazine; Female; Humans; Hypersensitivity, Delayed; Immunoglobulins; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 1977 |
Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
Topics: Adult; Antilymphocyte Serum; BCG Vaccine; Cytotoxicity Tests, Immunologic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunosuppressive Agents; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Skin Neoplasms; Structure-Activity Relationship; Triazenes | 1977 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1977 |
Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
Topics: Adult; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Triazenes | 1977 |
[Modern trends in the therapy of malignant melanoblastoma (author's transl)].
Topics: Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 1976 |
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Triazenes; Vincristine | 1976 |
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunization; Immunotherapy; Male; Melanoma; Middle Aged; Retroperitoneal Neoplasms; Skin Neoplasms; Vincristine | 1975 |
[Treatment of malignant melanomas. Trial of D.T.I.C. by intra-arterial infusion].
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Drug Evaluation; Female; Humans; Injections, Intra-Arterial; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Procarbazine; Remission, Spontaneous; Skin Neoplasms; Triazenes; Vincristine | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Skin Neoplasms; Vinca Alkaloids | 1975 |
[Non-surgical treatment of melanoma].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Skin Neoplasms | 1976 |
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes; Vincristine | 1976 |
Fotemustine plus dacarbazine for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Splenic lymphoma in a patient treated with interleukin-2 and dacarbazine for metastatic melanoma.
Topics: Adult; Dacarbazine; Humans; Interleukin-2; Lymphatic Metastasis; Lymphoma; Male; Melanoma; Skin Neoplasms; Splenic Neoplasms | 1992 |
Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma.
Topics: Adult; Brain; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Lymphatic Metastasis; Magnetic Resonance Imaging; Melanoma; Quadriplegia; Skin Neoplasms; Tomography, X-Ray Computed | 1992 |
Impaired levodopa response in Parkinson's disease during melanoma therapy.
Topics: Adult; Dacarbazine; Dopamine; Drug Interactions; Humans; Levodopa; Male; Melanins; Melanoma; Parkinson Disease; Skin Neoplasms | 1992 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen | 1992 |
[Breast metastases of skin melanoma].
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Dacarbazine; Female; Humans; Interferons; Male; Melanoma; Skin; Skin Neoplasms | 1990 |
Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Melanoma; Nitrogen Mustard Compounds; Rats; Rats, Nude; Skin Neoplasms; Transplantation, Heterologous | 1992 |
The prognosis of melanoma patients with metastases to two or more lymph node areas.
Topics: Adolescent; Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lomustine; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Prognosis; Skin Neoplasms; Survival Rate | 1991 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen; Thrombocytopenia | 1991 |
Metastatic malignant melanoma in pregnancy.
Topics: Dacarbazine; Female; Humans; Infant, Newborn; Melanoma; Pregnancy; Pregnancy Complications, Neoplastic; Skin Neoplasms | 1990 |
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1990 |
[The prevention of skin melanoma metastases to the regional lymph nodes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Humans; Injections, Intralymphatic; Lymphatic Metastasis; Melanoma; Methotrexate; Postoperative Care; Prospidium; Remission Induction; Skin Neoplasms | 1990 |
[Hepatic veno-occlusive disease caused by Deticene: a cause of acute hypovolemic shock].
Topics: Abdominal Pain; Ascites; Dacarbazine; Female; Hemodynamics; Hepatic Veno-Occlusive Disease; Humans; Hydrocortisone; Melanoma; Middle Aged; Shock; Skin Neoplasms | 1990 |
[Diagnosis and treatment of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Humans; Lymph Node Excision; Melanoma; Nimustine; Nitrosourea Compounds; Peplomycin; Prognosis; Skin; Skin Neoplasms; Vincristine | 1985 |
[Therapeutic response of interferon-beta in malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Indomethacin; Infusions, Parenteral; Interferon Type I; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1986 |
Expression of the c-src protooncogene in human skin tumors.
Topics: Adult; Aged; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nevus; Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins pp60(c-src); RNA, Messenger; Skin Neoplasms | 1987 |
[Successful therapy of secondary melanoma of the orbit with DTIC].
Topics: Aged; Dacarbazine; Facial Neoplasms; Humans; Male; Melanoma; Orbital Neoplasms; Palliative Care; Skin Neoplasms | 1987 |
Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Vincristine | 1989 |
Malignant melanoma infiltrating the reticular dermis at level IV.
Topics: Dacarbazine; Female; Humans; Interferons; Melanoma; Middle Aged; Referral and Consultation; Skin Neoplasms; Wrist | 1989 |
Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Vindesine | 1989 |
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Skin Neoplasms; Vinblastine; Vindesine | 1985 |
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Dacarbazine; Humans; Ifosfamide; Lung Neoplasms; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 1989 |
Tourniquet infusion chemotherapy of the lower extremities--clinical and pharmacokinetic results.
Topics: Adult; Aged; Dacarbazine; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tourniquets | 1989 |
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Vindesine | 1989 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombophlebitis | 1989 |
Peripheral DTIC neurotoxicity: a case report.
Topics: Aged; Dacarbazine; Humans; Lung Neoplasms; Male; Melanoma; Peripheral Nervous System Diseases; Skin Neoplasms | 1987 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms, Unknown Primary; Prognosis; Skin Neoplasms; Statistics as Topic; Tegafur; Vincristine | 1986 |
[Problems and results of treatment of 43 patients with melanomas of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Surgical Flaps | 1988 |
[Systemic therapy of metastatic malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Killer Cells, Natural; Lomustine; Melanoma; Skin Neoplasms | 1988 |
[Regional intra-arterial chemotherapy with Dacarbazine in isolated liver metastases of a malignant melanoma].
Topics: Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Liver Neoplasms; Melanoma; Middle Aged; Skin Neoplasms | 1988 |
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
Topics: Aged; Budd-Chiari Syndrome; Combined Modality Therapy; Dacarbazine; Eosinophilia; Fever; Humans; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms | 1988 |
[Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Topics: BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Injections, Subcutaneous; Melanoma; Middle Aged; Skin Neoplasms; Skin Ulcer | 1988 |
Treatment of advanced malignant melanoma with interferon alpha and etretinate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etretinate; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Skin Neoplasms; Vindesine | 1988 |
[Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prognosis; Skin Neoplasms | 1988 |
[DTIC: effect on fibrinolysis and thrombocyte function].
Topics: Blood Coagulation Tests; Budd-Chiari Syndrome; Dacarbazine; Fibrinolysis; Humans; Melanoma; Platelet Aggregation; Platelet Count; Skin Neoplasms | 1986 |
Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Melanoma; Middle Aged; Skin Neoplasms | 1987 |
[Late results of the conservative treatment of melanoma of the skin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Humans; Melanoma; Skin Neoplasms; Vincristine | 1986 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Neoplasm Recurrence, Local; Postoperative Care; Skin Neoplasms; Time Factors | 1987 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Kidney Diseases; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombocytopenia; Thromboembolism; Vomiting | 1987 |
Acute non-lymphocytic leukemia (ANLL) following treatment with dacarbazine for malignant melanoma.
Topics: Acute Disease; Dacarbazine; Humans; Leukemia; Male; Melanoma; Middle Aged; Muramidase; Scalp; Skin Neoplasms | 1987 |
[Clinical trials of supplementary chemotherapy in cases of malignant melanoma of the skin with unfavorable prognosis after surgical treatment].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Vinblastine | 1987 |
Adjuvant and neoadjuvant chemotherapy with dacarbazine in high-risk childhood melanoma.
Topics: Child; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Male; Melanoma; Retrospective Studies; Skin Neoplasms | 1987 |
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Evaluation Studies as Topic; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiotherapy Dosage; Skin Neoplasms; Time Factors | 1986 |
[Phase II study of decarbazine (DTIC) in malignant melanoma. DTIC Research Group].
Topics: Adolescent; Adult; Aged; Child; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms | 1986 |
Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Vindesine | 1986 |
Radiation in combination with intra-arterial infusion therapy with dacarbazine for metastatic malignant melanoma localized to a lower extremity.
Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Nausea; Neoplasm Recurrence, Local; Radiography; Skin Neoplasms | 1986 |
[Prognosis-oriented therapy of malignant melanoma. New concepts].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lymph Node Excision; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Risk; Skin; Skin Neoplasms | 1986 |
[Therapy and prognosis of malignant melanoma of the skin].
Topics: Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms | 1986 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Tamoxifen | 1986 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon Type I; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Vincristine | 1987 |
Applicability of high-dose chemotherapy with autologous marrow transplantation for malignant melanoma.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow Transplantation; Dacarbazine; Humans; Leukemia; Melanoma; Skin Neoplasms | 1985 |
Assessment of survival rates with metastatic malignant melanomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms | 1986 |
Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Hyperthermia, Induced; Leukopenia; Liver; Male; Melanoma; Middle Aged; Skin Neoplasms; Technetium Tc 99m Aggregated Albumin | 1986 |
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
Topics: Budd-Chiari Syndrome; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Skin Neoplasms | 1985 |
Arterial infusion of dacarbazine and cisplatin for recurrent regionally confined melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Vulvar Neoplasms | 1985 |
[Radiotherapy with intra-arterial chemotherapy. Treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide. Effect in malignant melanoma of the extremities].
Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Skin Neoplasms | 1985 |